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1.1 Multiple sclerosis 
1.1.1 Pathogenesis 
Multiple sclerosis (MS) is a chronic disease characterized by inflammatory demyelination 
and neurodegeneration occurring either focally or diffusely throughout the white and grey 
matter in the central nervous system (CNS) (Lassmann et al., 2012). MS is presumed to 
be of autoimmune origin, however the exact pathogenesis is not fully understood (Breuer 
et al., 2019). It is considered that genetic and environmental factors contribute to an 
increased risk of developing MS (Ascherio and Munger, 2016). Those factors with most 
supporting evidence are the Epstein-Barr virus, smoking cigarettes and vitamin D defi-
ciency (Amato et al., 2017; O'Gorman et al., 2012; Pugliatti et al., 2008). Furthermore, 
there is a geographic variation in the distribution of MS. It is more common in regions 
with temperate climate than in those with tropical climate (Simpson et al., 2011; Wallin 
et al., 2019). 
1.1.2 Clinical manifestation 
MS can cause a variety of neurological symptoms, since any region of the CNS can be 
affected by the disease (Ghasemi et al., 2017). However, in the course of the disease, 
patterns of abnormalities emerge: MS commonly manifests with sensory, motor, visual 
or cerebellar dysfunctions as well as fatigue (MSIF, 2013). In later stages of the disease 
patients may also be affected by bowel, bladder and sexual dysfunction (Stuke et al., 
2008). Table 1 lists the frequency of common symptoms by disease duration.  
Symptoms Disease duration <2 years (%) 
Disease duration 
> 15 years (%) 
Neuropsychological 
Fatigue 40.6 67.6 
Cognitive dysfunction 19.6 40.6 
Depression 23.6 38.0 
Motoric dysfunction 
Spasticity 17.3 75.8 
Ataxia/ tremor 24.4 56.5 
Others 
Pain 24.6 42.2 
Bladder dysfunction 20.5 74.0 
Bowel dysfunction 4.8 31.1 
Sexual dysfunction 8.0 27.3 
Others 2.1 3.9 
Table 1: Frequency of symptoms in patients with MS by disease duration. 
Reproduced with modifications from Stuke et al. (2008). 
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1.1.3 Descriptive epidemiology 
Approximately 2.2 million people worldwide are affected by MS. The risk of developing 
the disease is more than two times higher in women than in men (Compston and Coles, 
2008; Wallin et al., 2019). So far, nationwide population-based data on the prevalence 
(number of patients alive at a specific time per 100,000 person) of MS are not available 
in Germany and estimates are based on extrapolations from regional studies. Prevalence 
was estimated at 289 cases per 100,000 insured individuals in 2010, with 70% of those 
affected being female according to an analysis of statutory health insurance (SHI) data 
(Petersen et al., 2014). Globally, the prevalence of MS increases which might be ex-
plained by a decrease in disease-related mortality (Wallin et al., 2019). 
The incidence rate (number of new cases per 100,000 persons in one year) increases 
over time partially due to improvements in diagnostic techniques and a heightened 
awareness of the disease (Compston and Coles, 2008). The incidence rate is estimated 
at 8.0 cases per 100,000 person annually in Germany (Fasbender and Kölmel, 2008). 
Disease onset is mostly reported between 20-40 years of age and peaks at 34.4 years. 
Although the accumulation of disability is not the primary cause of death, life expectancy 
is on average 6-12 years shorter compared to the general population (Grytten Torkildsen 
et al., 2008; Kingwell et al., 2012; Ragonese et al., 2008).  
 
1.1.4 Clinical hallmarks and outcome measures 
1.1.4.1 Relapses 
Relapses and disability worsening are the clinical hallmarks of MS (Giovannoni et al., 
2016). A relapse is defined as a worsening or appearance of new neurological symptoms 
during acute or subacute disease activity in the absence of fever or infection lasting more 
than 24 hours followed by a period of partial or complete recovery (Lublin et al., 2014; 
McDonald et al., 2001). Relapses have a substantial impact on a variety of functioning 
on physical and mental health scales (Healy et al., 2012). Prevention of relapses is a 
main treatment target of disease modifying therapies (DMTs). In clinical trials, relapse-
based outcomes e.g. annualized relapse rate (ARR, defined as the number of confirmed 
relapses per patient adjusted for duration of follow-up) are a sound reflection of short 
term efficacy (van Munster and Uitdehaag, 2017). Further relapse-based outcomes are 
the average number of relapses per patient, proportion of (non-) relapsing patients and 




1.1.4.2 Disability worsening 
Disability worsening (confirmed disability worsening, CDW) refers to an accumulation of 
MS-related functional disability sustained over a predefined period usually three or six 
months (Kalincik et al., 2015; Uitdehaag, 2018; Wiendl and Meuth, 2015). It is objectified 
as changes in disability, most commonly defined as: ≥1.5-point increase for a reference-
score of 0; ≥1-point increase for a reference-score of 1.0-5.0; and ≥0.5 point increase for 
a reference score greater than 5.5 and as measured on the Expanded Disability Status 
Scale (EDSS) (Wiendl and Meuth, 2015). CDW can be either the result of relapse asso-
ciated worsening (RAW) or progression independent of relapse activity (PIRA) (Kappos 
et al., 2018b). While RAW can result from poor recovery from multiple or severe relapse 
activities, PIRA may indicate a progressive clinical course characterized by neurodegen-
erative processes independent of inflammation (Kappos et al., 2018a; Lublin et al., 
2014). 
The disability status scale (DSS) was published in the 1950s and subsequently modified 
until it was reissued in 1983 as EDSS (Kurtzke, 1955; Kurtzke, 1983). The EDSS is the 
most commonly used measure of neurological disability in MS clinical trials. Disability is 
assessed by capturing limitations in functional systems including vision, bowl, bladder, 
brainstem, the pyramidal system, the cerebellar system, the cerebral and the sensory 
system. In addition, it covers ambulatory endurance and the ability to perform activities 
of daily living. The scale ranges from 0 (normal neurological examination) to 10 (death 
due to MS) with half point steps between 1 and 10. The calculation of scores is subject 
to criticism (Cohen et al., 2012). While scores of 0-4.0 measure impairments in functional 
systems, scores above 4.0 are reflecting disability (van Munster and Uitdehaag, 2017). 
Thereby, ambulatory endurance and the need of assistive devices primarily determine 
scores between 4.0-7.0 and scores between 7.0-9.5 are based on the ability to carry out 
activities of daily living (van Munster and Uitdehaag, 2017). Further shortcomings are the 
non-linearity leading to a bimodal distribution and the limited ability to capture cognitive 
impairments. Figure 1 gives an overview of characteristics and caveats of the EDSS 




Figure 1: Characteristics and limitations of the Expanded Disability Status Scale.  
Reproduced with modifications from van Munster and Uitdehaag (2017). 
 
1.1.5 Clinical course 
Four clinical courses of MS can be distinguished and are visualized in figure 2: Relaps-
ing-remitting (RR), secondary progressive (SP), primary progressive (PP) and progres-
sive relapsing (PR) (Lublin et al., 2014). The majority of patients (85%-90%) initially ex-
perience a RR course characterized by episodic symptoms (relapses) with full or partially 
recovery (remitting) (MSIF, 2013). Up to 80% of patients transit to the SP course within 
20 years marked by continuous neurological decline with or without relapses (MSIF, 
2013). So far, no precise clinical, imaging, immunological or pathological criteria exist to 
define the transition point from RRMS to SPMS (Lublin et al., 2014). Approximately 10-
15% of people with MS exhibit an initial steady progressive deterioration in neurological 
functions with relapses (PR) or without relapses (PP) (Lublin et al., 2014; Miller and 
Leary, 2007). The pathological features of inflammation and neurodegeneration are pre-
sent in all clinical subtypes but vary qualitatively and quantitatively over time (Grigoriadis 
and van Pesch, 2015; Lassmann et al., 2012). While inflammation is more distinct in the 
acute relapsing phases of the disease, the key mechanism of disease progression might 
be a neurodegenerative process that is independent of inflammation (Correale et al., 




Figure 2: Classification of the clinical courses of multiple sclerosis.  
Reproduced with modifications from Grigoriadis and van Pesch (2015). 
 
1.1.6 Disease modifying therapies 
There is no curative treatment for MS available. Treatments aim at reducing the risk of 
relapses and slowing disability worsening (Montalban et al., 2018). Since the approval 
of interferon in 1993, neurologists and patients have seen a variety of therapeutic options 
including injectable and oral formulations approved by the European Medicines Agency 
(EMA) for the treatment of MS (De Angelis et al., 2018). First line DMTs for low and 
moderate active RRMS include interferon beta-1b (IFN-ß-1b), interferon beta-1a (IFN-ß-
1a), glatiramer acetate (GA), teriflunomide and dimethyl fumarate while fingolimod is ap-
proved for treatment of patients who are insufficiently treated with first line therapies. 
Treatment options for patients with highly active MS include apart from first line treat-
ments fingolimod, natalizumab, alemtuzumab, cladribine and ocrelizumab (Rommer et 
al., 2019). In the following analyses, patients were treated either with INF-ß or with GA. 
These medications are introduced shortly. 
The mechanisms of action of IFN-ß and GA are multifactorial and not fully understood. 
It is evident that broad immunomodulatory effects are generated on multiple levels of the 
immune response (Aharoni, 2013; Kieseier, 2011). The safety and efficacy profile of INF-
ß and GA including clinical and magnetic resonance imaging (MRI) measures show only 
small differences (La Mantia et al., 2016). Both treatments are associated with a ≈30% 
reduction in risk of confirmed relapses compared to placebo (Khan et al., 2013; Killestein 
and Polman, 2011). The efficacy of INF-ß in reducing confirmed disability worsening is 
divergent (Kappos et al., 2004). An European study showed that IFN-ß significantly 
slowed confirmed disability worsening while an American study could not confirm this 
effect (Kappos and European Study Group on Interferon β-1b in Secondary Progressive 
MS, 1998; The North American Study Group on Interferon beta-1b in Secondary 
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Progressive MS, 2004). In summary, response to IFN-ß and GA is highly heterogeneous 
and in some patients, disease activity is insufficiently controlled (Ziemssen et al., 2015a). 
 
Fingolimod, the first available oral agent, is a sphingosine 1-phosphate receptor modu-
lator that prevents the egress of autoreactive lymphocytes from lymph nodes, leading to 
reduced infiltration of potentially autoaggressive lymphocytes into the CNS (Chun and 
Hartung, 2010). Fingolimod reduced the annualized relapse rate by 48-60% compared 
to placebo and by 38-52% compared to INF-ß 1a (Calabresi et al., 2014; Cohen et al., 
2010; Kappos et al., 2010). A significant effect on confirmed disability worsening after 
three and six months was observed in one out of three clinical phase II trials (Calabresi 
et al., 2014; Cohen et al., 2010; Kappos et al., 2010). In RWE, analyses it was further 
confirmed that switching therapy from IFN-ß and GA to fingolimod rather than to another 
injectable is beneficial in terms of fewer relapses, more favorable disability outcomes 
and greater treatment persistence (Alsop et al., 2017; He et al., 2015).  
 
1.1.7 Natural history 
The natural history of MS is determined by the frequency of relapses as well as disability 
worsening. The average relapse rate is age- and time-dependent. It is higher in young 
adulthood and decreases significantly in the course of the disease from 1.85 ARR in the 
first year after onset to 0.2 ARR after 19 years (Patzold and Pocklington, 1982). In RRMS 
the ARR is considered to be 0.5 on average (Confavreux et al., 1980). After 18 years 
about 50% of the patients have reached a disability level, so they need a walking aid to 
walk 100m (EDSS 6.0) (Scalfari et al., 2010). However, more recent investigations have 
shown that disability worsening accrued more slowly than previously reported with me-




1.2 Cost of illness research 
Cost of illness (CoI) refers to the economic framework that is used to estimate the costs 
of a particular disease to society (Drummond, 2015; Rice, 1967). CoI studies offer valu-
able insights for improving societal welfare in different manners. First, they can help to 
detect the drivers of diagnosis and treatment costs of a specific disease (Simoens, 2009). 
Second, CoI studies may help ranking diseases according to their burden to society and 
hence to determine priorities in medical research (Drummond, 1992; Tarricone, 2006). 
They are particularly valuable in addition to epidemiological studies. For example, mor-
bidity and mortality are essential factors to estimate the burden of disease but offer lim-
ited insights on the consequences of impaired health (WHO, 2009). CoI studies capture 
the economic consequences like productivity losses or escalation in out of pocket pay-
ments that are potentially fatal in chronic, progressive diseases like MS. Third, data from 
CoI studies can be used in full economic evaluation in which both costs and conse-
quences of two or more interventions are evaluated (Simoens, 2009). The value of CoI 
research is reflected in its frequent use of policy makers and institutions like the World 
Health Organization (WHO). 
Chapters 1.2.1-1.2.3 provide a methodological review of CoI studies. The application of 
the methods is subsequently described in the empirical part of the thesis. 
 
1.2.1 Classification of costs 
CoI studies stratify costs into direct medical, direct non-medical and indirect costs. Direct 
medical costs refer to resource utilization resulting directly from health care interventions, 
for example physician consultations, in- and outpatient stays and medication (Jo, 2014). 
Direct non-medical costs arise from resource utilization with a supportive character for 
the health system such as transportation to the hospital, informal care from family mem-
bers and friends or reconstruction in a patients home due to disability caused by the 
illness (Jo, 2014). Indirect costs refer to productivity loss due to a disease (Segel, 2006). 
They result from not showing up for work (absenteeism) or from reduced productivity at 
work (presenteeism). Indirect costs are particularly high in chronic illnesses like MS. An 




Direct medical resources Direct non-medical resources Indirect resources 
Inpatient care 
Outpatient care 
Home health care 





























Table 2: Exemplary resource items by cost categories.  
Reproduced with modifications from Jo (2014). 
 
So-called intangible costs describe the burden resulting from pain and suffering meas-
ured by reduction in quality of life. Intangible cost are not economic costs and usually not 
monetized (Larg and Moss, 2011). According to the Institute for Quality and Efficiency in 
Health Care (IQWiG) intangible costs should be reported as a negative benefit on the 
outcome side in health economic assessments (IQWIG, 2017). 
 
1.2.2 Costing methodologies 
Costing methodologies can be described by the underlying process of resource identifi-
cation (microcosting- vs. gross costing) and resource valuation (top-down vs. bottom-up) 
(Luce et al., 1996; Tan et al., 2009).  
Microcosting involves the “direct enumeration and costing out of every input consumed 
in the treatment of a particular patient” (Luce et al., 1996). For example, in hospital ser-
vices laboratory tests, medical consumables and surgical interventions might be identi-
fied (Ljungqvist et al., 2017). In contrast, gross costing identifies only a limited number 
of cost components. For example, inpatient stays might be used as a surrogate for hos-
pital services. Both, micro- and gross costing can be applied as top-down or bottom-up 
approaches.  
The top-down approach calculates average service or unit costs by dividing total costs 
by the number of cost drivers (e.g. number of patients) (Raulinajtys-Grzybek and 
Świderska, 2015). The bottom-up approach values each service provided with the re-
sources used, resulting in patient specific service or unit costs (Cunnama et al., 2016; 
Raulinajtys-Grzybek and Świderska, 2015). Combining valuation and identification meth-
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odologies gives four costing methodologies as shown in figure 3: Bottom-up microcost-
ing, top-down microcosting, bottom-up gross costing and top-down gross costing (Tan 
et al., 2009). 
 
Figure 3: Overview of costing methodologies.  
Reproduced with modifications from Tan, et al. (2009). 
 
Bottom-up microcosting is believed to be the gold standard since costs are assigned to 
individual services at a level that reflects the patients’ actual consumption of resources 
(Raulinajtys-Grzybek and Świderska, 2015; Ruger and Reiff, 2016). This methodology 
enables statistical analyses to detect differences in costs between subgroups as well as 
sensitivity analyses to handle uncertainty (Smith and Rudmik, 2013). On the downside, 
its feasibility is challenging since bottom-up microcosting is time and cost consuming 
(Tan et al., 2009). 
A frequently used alternative is the top-down microcosting approach that assigns total 
costs to a detailed enumeration of services provided. It is more feasible compared to 
bottom-up microcosting (Tan, et al., 2009). Nevertheless, statistical analysis of patient- 
or disease strata are more restricted.  
In bottom-up gross costing resources are valued highly accurate but identified at an ag-
gregated level. At the least accurate level, top-down gross costing assigns aggregated 
values to average patients (Tan et al., 2009).  
Gross costing approaches have the disadvantage that the less resource items are iden-
tified, the more equal patients are handled even though they obviously have dissimilar 
costs (Tan, 2009). In complex diseases like MS, patients’ needs cover a wide range of 
costly resources and a gross costing approach is inadequate. Due to the aforementioned 
advantages, bottom-up microcosting is used in the following study. 
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1.2.3 Process of cost estimation 
The process of cost estimation includes the identification of resource consumption linked 
with a particular disease, the quantification of these resources as well as the valuation 
with corresponding prices weights to obtain costs.  
1.2.3.1 Identification of resource use - relevance of the perspective 
Identification of resources is highly dependent on the study perspective (Segel, 2006). 
Commonly studies are conducted from the perspective of the society, SHI or SHI plus 
patients (Table 3) (IQWIG, 2017).  
The societal perspective is the broadest encompassing all direct (non-)medical and indi-
rect costs regardless who is bearing them. Generally, the societal perspective is pre-
ferred by economists since it minimizes potential biases of narrower views (Dagenais et 
al., 2008; Graf von der Schulenburg et al., 2007; van Lier et al., 2018). For example from 
a societal perspective, transfer payments (e.g. sickness benefits) are not considered as 
resources. They are only shifted from one group (workers) to another (workers on sick 
leave) without changing the value of resources within the society (Russell et al., 1996).  
The SHI perspective considers all costs that are refunded by the SHI. Included are trans-
fer payments (e.g. sickness benefits) which represents a loss of resources from the view-
point of the SHI. The SHI plus patients-perspective additionally includes patients’ own 
expenses but transfer payments are not considered.  
Various sources can be used to identify cost-causing events. During the cost identifica-
tion process, it is recommended to use a decision tree showing the pathways of all events 
of a patient’s journey. Previous studies, pretrial data collections, pilot tests, modellings, 



























✔ ✔ ✔ ✔ ✘ ✘ 
SHI ✘ ✘ ✔ ✘ ✘ ✔ 
Table 3: Perspective of cost estimation and relevant cost categories.  
Abbreviations: statutory health insurance (SHI). 
Reproduced with modifications from IQWIG (2017). 
1.2.3.2 Quantification resource consumption 
Resource use data are often taken secondarily from sources like administrative datasets 
or they are collected primarily alongside clinical trials. Administrative data are mostly 
standardized, reliable and accessible and therefore superior to primary data in specific 
cases (Franklin and Thorn, 2019). However, data accuracy might be limiting, as several 
healthcare services can – but should not – be combined under one caption. Furthermore, 
administrative data underlie the limitations that no societal perspective can be adopted 
since not all relevant resources are recorded (e.g. informal care or presenteeism) (Martin 
et al., 2012). Furthermore, administrative data do not contain clinical data, making it dif-
ficult to identify reasons for cost differences in subpopulations.  
Diaries and questionnaires are frequently used to gather data primary alongside clinical 
trials (O'Sullivan et al., 2005). Patient diaries are completed after services have been 
received or on regular sequence of short time intervals (e.g. per day). Therefore, diaries 
are limiting the risk of recall biases which might occur in questionnaires (Ridyard et al., 
2015). Although, resource use diaries are well suited for cross-sectional and short-term 
data collections, considerable problems regarding dropout rates and thoroughness in 
reporting are challenging for data collections expanding twelve months (Fowler and 
Floyd, 1993). Therefore, questionnaires might better suit health economic data collection 
with time periods longer than one year (Schweikert et al., 2008).  
Self-reported questionnaires can be distinguished in disease-specific and generic instru-
ments (Leggett et al., 2016). While disease-specific instruments are adapted to the spe-
cific needs of a patient population, generic instruments target more broad population. 
Especially in complex conditions like MS, disease specific measures are necessary to 
collect relevant resources comprehensively.  
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To avoid issues of recall bias in self-reported health resource surveys recall periods 
should be determined based on cognitive theories. Recall biases have two main causes: 
First, more common and less striking events are less likely to be recalled precisely over 
a long period. Second, long recall periods cause telescoping effects in which events out-
side the targeted period are incorrectly assigned in the recall period.  
1.2.3.3 Valuation of resource consumption 
Resource valuation is the assignment of an economic price to a resource item. In studies 
conducted from a societal perspective resource prices should reflect the societal oppor-
tunity costs. These are defined as the value of the lost benefits, as resources are not 
available for its best alternative use (van Lier et al., 2018).  
 
Valuation of direct medical costs 
Societal opportunity costs and market prices are equal on perfectly competitive markets. 
Nevertheless, the healthcare market is imperfect for the sake of statutory regulations. 
Therefore, societal opportunity costs have to be approximated in most cases using e.g. 
published data for standardized cost units (Bock et al., 2015). For medical procedures 
(examinations, lab tests and diagnostic imaging) it is recommended to use bargaining 
prices e.g. the physicians’ Fee Schedule that is negotiated between the National Asso-
ciation of Statutory Health Insurance Physicians and the Central Federal Association of 
Health Insurance Funds (IQWIG, 2008).  
When medication costs are a large proportion of the direct costs, it is highly recom-
mended to use an accurate medication cost method (Heslin et al., 2018; Kobelt et al., 
2017b). A recommended approach would be to (i) calculate costs per milligram for each 
medication on the basis of most cost-efficient pack sizes and (ii) apply these unit costs 
to the reported doses (Heslin et al., 2018).  
 
Valuation of informal care costs 
In contrast to formal care, informal care is provided by family members, friends and 
neighbors (Oliva-Moreno et al., 2019). Informal care is especially relevant in diseases 
that cause significant restrictions on a person’s autonomy and therefore a distinctive de-
mand for care (Jimenez-Martin and Prieto, 2012). Even though informal care is often 
provided without monetary compensation there are hidden costs for the caregivers such 
as a decrease in labor supply (Oliva-Moreno et al., 2017). The two mainly used methods 
to value informal care costs in CoI studies are the opportunity costs method (69% of 
cases) and the proxy good method (27% of cases) also known as replacement cost ap-
proach (Oliva-Moreno et al., 2017). In the former, informal care time is valued at the 
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opportunity costs out of the perspective of the caregiver (Landfeldt et al., 2019). The 
opportunity costs are mostly based on average wages or derived from estimating tech-
niques like conjoint analysis or contingent valuation (Landfeldt et al., 2019). The proxy 
good method values informal care activities at a shadow market price like a housekeeper 
for housekeeping service. It is frequently debated which of the two methods should be 
used (Pike and Grosse, 2018). For analysis from a societal perspective the opportunity 
cost method is the recommended technique as these are an adequate approximation 
(Landfeldt et al., 2019).  
 
Valuation of indirect costs 
The two main approaches to estimate indirect costs are the friction cost method and the 
human capital approach. In the latter lost productivity is valued at the opportunity cost of 
labor using the cost of employment e.g. the national mean wage plus employer’s cost 
and social fees (Landfeldt et al., 2019). Using the friction cost method productivity losses 
only occur during the friction period, the time it takes to replace a worker taken from the 
pool of unemployed (Landfeldt et al., 2019). While the friction cost method underlies the 
highly unrealistic assumption that labor supply is fully elastic, the human capital approach 
is criticized for not taking into account the possibility of replacement even if the unem-
ployment rate is significantly high (Jo, 2014; Pike and Grosse, 2018). A recent review 
revealed that more than 90% of CoI-studies evaluated productivity loss using the human 
capital approach which is also in line with most countries health technology assessment 
recommendations (Pike and Grosse, 2018). 
Prices from different periods should be adjusted using country specific discount rates 
and the formula: 
 









1.3 Cost of multiple sclerosis 
The economic burden associated with MS is tremendous for patients, caregivers, 
healthcare providers and society. The chronic and mostly progressive nature of MS leads 
to long-term treatment with expensive DMTs. Continuous monitoring of clinical and MRI 
activity as well as further examinations are needed to determine response to DMTs 
(Gasperini et al., 2019). Additional management of new or worsening symptoms might 
require interdisciplinary collaboration of a wide range of specialists including neurolo-
gists, physiotherapists or occupational therapists. In later stages of the disease, produc-
tivity restrictions and informal care lead to further demand for societal resources.  
The following chapters summarize the state of research on the cost of MS. Chapter 1.3.1 
reviews instruments used to date to assess the economic burden. Chapter 1.3.2 reviews 
relevant CoI studies with a focus on disease worsening and relapses burden.  
1.3.1 Instruments for resource use measurement 
Despite the long tradition of health economic analysis in MS, there is no validated instru-
ment available to measure resource costs associated with MS (D'Amico et al., 2019; 
DIRUM, 2019; Leggett et al., 2016). Even though Kobelt et al. (2019b) recently recog-
nized the need for an instrument for resource use measurement in MS, validating and 
publishing an instrument still remains a task to fulfil. Considerable research time is re-
peatedly spent to develop study-specific instruments. Nevertheless, the psychometric 
properties of these instruments are scarcely analyzed or re-validated if used in a modified 
manner (Franklin and Thorn, 2019; Ridyard and Hughes, 2010). To address this issue, 
the DIRUM database was established to provide an open-access database of instru-
ments for resource use measurement (DIRUM, 2019).  
Besides disease-specific instruments, universal instruments exist (McCrone et al., 2008). 
The Client Service Receipt Inventory (CSRI) might be the most widely spread universal 
instrument with over 200 modifications for different disease areas, healthcare systems, 
languages and types of applications (Beecham and Knapp, 1992; Thorn et al., 2013). 
The original questionnaire gathers data on the individual background, accommodation 
and living situation, employment, social security benefits, healthcare services and infor-
mal care (Beecham and Knapp, 1992; Thorn et al., 2013). Psychometric properties have 
been assessed in different settings with overall good results (Byford et al., 2007; Leggett 
et al., 2016; Roick et al., 2001). Furthermore, the Annotated Patient Cost Questionnaire 
(APCQ) is a universal instrument (Thompson and Wordsworth, 2001). It compromises a 
collection of questions to simplify the transfer of the APCQ into different contexts (Thorn 
et al., 2013). Even though the questionnaire might perform well, it is not widely adopted 
15 
 
yet (Thorn et al., 2018). However, the usefulness of both of the aforementioned ques-
tionnaires is limited in complex diseases like MS because MS patients’ needs extend the 
resources that are captured in those instruments. 
Standardized instruments additionally exist that concentrate on specific cost components 
(Landfeldt et al., 2019; Reilly et al., 1993). For example the Work Productivity and Activity 
Impairment Questionnaire (WPAI) is a widely spread instrument to assess absenteeism, 
presenteeism, overall work performance and non-work activities for general health 
(WPAI:GH) or specific health problems (WPAI:SHP) including MS (WPAI:MS) (Chen et 
al., 2018). The psychometric properties of the WPAI have been analyzed in several 
chronic diseases with overall good results (Lambert et al., 2014; Reilly et al., 2004; Reilly 
et al., 2010).  
Recently, a list of core items was published by an expert consensus that should be in-
cluded in instruments for resource use measurement from the provider perspective 
(Thorn et al., 2018). The list gives a helpful orientation for the development of a new 
instrument (Table 4). However, it does not take into account disease specific resources. 
 
Type of care Item 
Hospital care 
Number of hospital admissions (inpatient stays/ day case) 
Length of stay (e.g. dates/ number of nights) 
Number of hospital outpatient appointments 
Emergency Care 
Number of visits to A&E 
Number of hospital visits after A&E 
GP surgery/ health clinic/ 
community setting 
Number of appointments 
Type of professional 
Home Care 
Number of visits 
Type of professionals 
Medication Name/class of medication 
Table 4: Recommended items for a resource use measure instrument.  
Abbreviations: accident and emergency (A&E); general practitioner (GP). 





1.3.2 Review of cost of multiple sclerosis studies in Germany 
Three academically highly relevant CoI studies analyzed the societal economic costs of 
MS comprehensively in Germany since 2010 (Table 5) (Flachenecker et al., 2017; 
Karampampa et al., 2012b; Reese et al., 2011). I do not consider studies published prior 
to 2010 due to the major changes in therapy and diagnostic options in recent years.  
 
 Flachenecker 2017 Karampampa 2012 Reese 2011 
Sample size (n) 5474 244 144 
Year of price level 2015 2009 2006 
Age (mean±SD) 51.8±11.0 41.2±9.9 41.7±11.3 
Female gender (%) 74% 69% 69% 
EDSS (mean±SD) 4.0±2.5 1.8±1.8 3.5±2.0 











Table 5: Study characteristics of cost of illness studies conducted in Germany since 2010. 
Abbreviations: Expanded Disability Status Scale (EDSS). 
Reproduced with modifications from Flachenecker et al. (2017); Karampampa et al. (2012b); 
Reese et al. (2011). 
 
The most recent and largest study (n=5457) was conducted by Flachenecker et al. and 
reported the German results of a CoI study rolled out throughout Europe. In comparison 
to Karampampa (2012) and Reese (2011) participants were older (51.8±11.0 vs. 
41.2±9.9 vs. 41.7±11.3) and more severely disabled (EDSS 4.0±2.5 vs. 1.8±1.8 vs. 
3.5±2.9). Karampampa et al. (2012b) provided results for Germany of a European study 
with the sole characteristic that costs were also reported depending on the clinical course 
(RRMS, SPMS, PPMS). Reese et al. (2011) recruited 144 patients for their study. Con-
trary to the questionnaire-based methodology of Flachenecker and Karampampa, data 
were collected in a structured face-to-face interview. Table 6 summarizes the results of 







annual costs in € 
Karampampa 
20121,2, 5 
annul costs in € 
Reese  
20111,3 
annual costs in € 
Direct medical   18,958-16,521 18,395-32,928 24,037 
Inpatient 1236-6783 674-13,406 4833 
Outpatient 126-231 515-3875  
Physician 
consultations 1066-2317 589-2127 2211 
Investigations 324-201 107-68 -- 
DMTs 15,819-4891 15,204-11,900 16,486 
Medication 387-2098 1305-1552 507 
Direct non-medical  952-18,717 1262-23,198 877 
Informal care 721-15,280 901-18,360 -- 
Investments 231-3.437 361-4838 877 
Indirect  8190-21,586 3317-11,931 21,538 
Sick leave 723-108 1605-994 2037 
Presenteeism -- -- 667 
Disability pension, early 
retirement 7467-21,478 1712-10,937 18,834 
Table 6: Comparison of annual resource costs of studies conducted in Germany since 2010. 
1 Cost data are inflated to index year 2015 using the consumer price index and the formula 
stated in chapter 1.2.3.3. Discount rates are 8.5% and 14.2% for prices from 2006 and 2009, 
respectively.  
2 Costs depend on disease severity (EDSS 0-3 to EDSS 7-9). 
3 Contrary to the original categorization, investments were allocated to direct non-medical costs 
instead to direct medical costs. 
4 To ensure comparability, community services were not considered in direct non-medical costs 
5 To ensure comparability, professional care was not considered in direct medical costs. 
Reproduced with modifications from Flachenecker et al. (2017); Karampampa et al. (2012b); 
Reese et al. (2011). 
 
Direct medical costs 
Considering the differing methodologies, study design as well as patient and disease 
characteristics, the three CoI studies are difficult to compare. However, tendencies can 
be deduced with caution. In the following paragraphs, the results of the above-mentioned 
studies are discussed. 
Annual direct medical costs ranged between 16,521€-32,928€ depending on disease 
severity as measured by EDSS. In mildly disabled patients, DMTs represented the larg-
est share of direct medical costs (15,204€-16,486€). In severely disabled patients, the 
share of DMTs decreased (4891€-11,900€) partially explained by the lack of treatment 
options for a progressive clinical course in later stages of the disease.  
Costs of inpatient hospitalization accounted for the second largest share of annual direct 
medical costs. They were mainly incurred in neurological wards (Flachenecker et al., 
2017). The economic burden rose significantly with increasing disability (1236€ (EDSS 
0-3)-13,406€ (EDSS 7-9)). Nevertheless, annual costs in the same EDSS categories 
varied widely (674€-1236€ (EDSS 0-3); 6783€-13,406€ (EDSS 7-9)), possibly due to 
different study methodologies.  
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Annual costs for outpatient physician consultations ranged between 1066€-2317€ de-
pending on the degree of disability. The most frequent consultations were with neurolo-
gists, physiotherapists and general practitioners (Flachenecker et al., 2017).  
Besides DMTs, symptomatic treatments contributed mainly to medication costs. Annual 
costs ranged with EDSS from 387€-1305€ (EDSS 0-3) to 1552€-2098€ (EDSS 7-9). Di-
agnostic services accounted for a small share of direct medical costs and ranged be-
tween 68€ (EDSS 0-3) and 324€ (EDSS 7-9). 
 
Direct non-medical 
Annual direct non-medical costs ranged between 952€-1262€ (EDSS 0-3) and 18,717€-
23,198€ (EDSS 7-9). Severely disabled patients were more dependent on informal care, 
which resulted in a large cost difference compared to mildly disabled patients (721€-
901€ (EDSS 0-3)-15,280€-18,360€ (EDSS 7-9)). Annual costs for investments (e.g. 
walking and mobility aids) and house or car modifications rose with increasing EDSS 
from 231€-361€ (EDSS 0-3) up to 3437€-4838€ (EDSS 7-9) (Flachenecker et al., 2017). 
 
Indirect costs 
The unfavorable diagnostic age caused annual indirect costs ranging between 3317€-
8190€ (EDSS 0-3) and 11,931€-21,586€ (EDSS 7-9). Increasing disability had two op-
posite effects: While annual costs for absenteeism decreased from 723€-1605€ (EDSS 
0-3) to 108€-994€ (EDSS 7-9), costs for disability pension and early retirement increased 
from 1712€-7467€ (EDSS 0-3) to 10,937€-21,478€ (EDSS 7-9). Increases in indirect 
costs were multifactorial: In the short term, fatigue and reduced mobility were associated 
with an increased number of sick leave (Wickstrom et al., 2014). In the long term, female 
gender, ≥ 51 years of age, moderate/ high disease severity and impaired manual dex-
terity were associated with higher rates of disability pension (Chruzander et al., 2016). 
Reese et al. (2011) further reported annually costs of presenteeism of 667€ per patient 
regardless of disease severity. 
 
Relapse associated costs 
The economic burden associated with relapses is significant (Naci et al., 2010). Almost 
all societal resources are increasingly used. The cost drivers during relapses are hospi-
talizations, physician consultations, informal care and sick leave (Hawton and Green, 
2016; Kobelt et al., 2017b). However, relapse costs can vary with relapse intensity rang-
ing from a single symptom lasting over a few hours up to a wide range of neurological 
dysfunctions remaining over weeks.  
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O'Brien et al. (2003) analyzed the direct medical costs associated with relapses stratified 
by relapse intensity. They reported relapse associated direct costs of 243 US$, 
1847US$, and 12,870US$ for mild, moderate and severe relapses, respectively. O'Brien 
et al. (2003) concluded that costs are more than 6-fold higher if relapses are treated in 
inpatient settings.  
Flachenecker et al. (2017) and Karampampa et al. (2012b) calculated relapse costs as 
the difference between quarterly costs of patients with and without relapses with results 
of 2468€ (price level 2015) and 5249€ (price level 2009), respectively. Patient and dis-
ease characteristics of these distinct populations were not presented. However, differ-
ences in relapse costs between subgroups are likely since relapses and the associated 
costs might vary across and within individuals with respect to disease severity, disease 
duration, gender or therapy (Derfuss et al., 2016; Hawton and Green, 2016; Kobelt et al., 




1.4 Hypotheses and objective  
MS is an incurable and progressive condition leading to tremendous suffering for patients 
and an enormous societal economic burden (Kobelt et al., 2017b; Wallin et al., 2019). 
The key clinical hallmarks of MS are relapses and disability worsening both associated 
with significantly increased utilization of direct and indirect resources (Naci et al., 2010). 
However, implications of relapses and disability worsening on societal economic costs 
have scarcely been studied. This is partly due to a lack of longitudinal data that are re-
quired for comprehensive analyses (Naci et al., 2010). Consequently, this thesis focuses 
on how clinical hallmarks in patients with MS affect the societal economic costs of the 
disease. The two hypotheses below are derived to address this research aim.  
Regarding disability worsening it is known that the overall economic burden increases 
as disease severity increases (Karampampa et al., 2012a; Kobelt et al., 2017b). Further-
more, the distribution of costs changes with increasing disease severity (Naci et al., 
2010). While DMTs are the main cost driver in the early stages of the disease, produc-
tivity losses account for the majority of costs for more severely disabled patients. How-
ever, the societal economic implications regarding disability worsening remain not well 
understood. The aforementioned observations lead to the first hypothesis: Societal eco-
nomic costs are significantly higher in patients with disability worsening compared to 
patients being free of disease activity.  
Research to date has shown that the economic burden of MS increases in periods of 
relapses. However, results are inconsistent between studies. This may arise from differ-
ent implications of relapses with respect to disease severity, age, disease duration or 
therapy. Kobelt et al. (2006b) suggested that relapses have a stronger implication in 
patients with limited disability. However, a comprehensive test of this hypothesis is still 
needed and thus constitutes the second hypothesis of this thesis.  
My second hypothesis is that young patients and those with a short disease duration 
have higher societal economic relapse costs than older patients and those with longer 
disease duration. 
Hence, this thesis determines priorities in medical research to reduce the societal eco-
nomic burden in patients with MS. A prerequisite is an instrument with sufficient psycho-
metric properties to assess the societal economic costs. Despite the long tradition of 
health economic evaluations in MS, there was no such instrument available (chapter 
1.3.1). Consequently, I first use and validate the instrument termed Multiple Sclerosis 




2 Data source 
Pooled two-year data were extracted from two single arm, prospective, multicenter, non-
interventional long term studies conducted in Germany. The Post-Authorization Non-In-
terventional German safety study of GilEnyA (PANGAEA) assessed the long term safety 
and efficacy of fingolimod. Beta interferons and glatiramer acetate (BRACE) therapies 
were assessed in the Prospective Pharmacoeconomic Cohort Evaluation (PEARL) 
(Vormfelde et al., 2016; Ziemssen et al., 2015b). Additionally, both studies collected 
pharmacoeconomic data. 
 
2.1 Study setting 
Recruitment into PANGAEA took place after market approval for fingolimod in April 2011 
until December 2013 for patients receiving 0.5 mg fingolimod daily. The observational 
period of the main and pharmacoeconomic substudy ended after 60 months in Decem-
ber 2018 and after 24 months in December 2015, respectively. Recruitment into PEARL 
took place between September 2010 and March 2011 for patients receiving BRACE ther-
apies for at least 30 days. The observational phase of the study ended after 24 months 
in March 2013. As the participants in both studies were recruited in Germany from over-
lapping centers and during an overlapping timeframe, the environmental and pharmaco-
economic conditions are expected to be similar (Alsop et al., 2017; Vormfelde et al., 
2016; Ziemssen et al., 2015b). An overview of the timeline is shown in figure 4. 
 




2.2 Clinical and economic data  
Study data were collected during routine physician consultations at baseline, every 3 
months during follow up and at the final visit after 24 months resulting in nine data entry 
points per patient. Demographic and clinical data were collected using interviews, exam-
inations and medical records. Patient-reported outcomes (PROs) were completed by 
participants on a regular basis using a (electronic) case report form (CRF) in the pres-
ence of a health care professional.  
Data on resource utilization, treatment satisfaction (Treatment Satisfaction Question-
naire for Medication (TSQM-9)) and compliance with the medication were collected every 
three months in the pharmacoeconomic (sub)study (Atkinson et al., 2004). Every six 
months patients reported their health-related quality of life (HRQoL) based on the Eu-
roQol-5 Dimensions (EQ-5D) and the Patient Reported Indices for Multiple Sclerosis 
(PRIMUS). Every 12 months activity limitations and neurological disability were assessed 
using the PRIMUS and the UK Neurological Disability Scale (UKNDS), respectively 
(Doward et al., 2009; Kind, 1990; Sharrack and Hughes, 1999). Data obtained in the 
studies are listed in table 7. 
Table 7: Clinical and patient reported data obtained during the studies.  
 
The EQ-5D is a generic instruments for assessing HRQOL with high psychometric prop-
erties (Fisk et al., 2005; Kind, 1990). The assessment is carried out by the test persons 
based on five dimensions: mobility, independence, everyday activities, pain and anxiety. 
These dimensions are evaluated on a three-level scale (EQ-5D-3L). The lowest value 
 Baseline visit Follow-up Final visit (24 months) 
Clinical Data 
EDSS  ✔ Every 6 months ✔ 
Relapse  
information ✔ Every 3 months ✔ 
Patient Reported Outcomes 
Consumption of re-
sources ✔ Every 3 months ✔ 
UKNDS ✔ At 12 months ✔ 
EQ-5D, PRIMUS-
A, PRIMUS-L ✔ Every 6 months ✔ 
Compliance ques-
tionnaire ✔ Every 3 months ✔ 
TSQM-9 ✔ Every 3 months ✔ 
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indicates no problems, the highest value extreme problems. Additionally, the respondent 
evaluates his HRQOL on a visual analogue scale ranging from zero to 100. This provides 
additional information that is not reflected in the previous dimensions.  
The PRIMUS measures MS-specific the HRQOL (PRIMUS-L) and activity limitations 
(PRIMUS-A) (Doward et al., 2009). Depending on the short or long form of the question-
naire, 45 or 22 dichotomous questions are recorded to determine the quality of life, where 
a high sum value indicates a low quality of life. The activity questionnaire comprises 15 
questions related to physical tasks on which respondents assess the degree to which 
they are capable of performing the tasks. A high score indicates a high activity restriction 
(McKenna et al., 2010). The reliability and validity of the three scales is rated as high, 
with the reliability for the scales for recording quality of life and activity restrictions is 
higher compared to the symptom scale (McKenna et al., 2010).  
The UKNDS measures the functional status of the patient in 13 mutually exclusive do-
mains (Heesen et al., 2007; Sharrack and Hughes, 1999). These are cognition, mood, 
vision, speech, swallowing, upper limb function, mobility, bladder function, bowel func-
tion, sexual function, fatigue, pain and "other" as a collective term of other unrecorded 
dimensions such as dizziness or cramps. Each domain is assessed by the respondent 
based on three to eight questions. The degree of impairment is converted from zero 
(normal function) to five (total loss of function) depending on the answers to an ordinal 
scale (Sharrack and Hughes, 1999). Rossier and Wade (2002) proved that the UKNDS 
is a reliable and valid instrument.  
The TSQM-9 is a psychometrically validated, generic measure to assess the patients’ 
treatment satisfaction with their medication (Atkinson et al., 2004). The TSQM-9 is based 
on the three scales that assess the patients’ perception of medication effectiveness, con-
venience and global satisfaction. Each scale comprises three items with answers rated 
from one (low) to seven (high) on a Likert scale. Higher scores on the TSQM-9 indicate 




2.3 Study population 
Patients were eligible to participate if they were diagnosed with RRMS and if they re-
ceived their medication in accordance with the summary of product characteristics. To 
be admitted to PANGAEA, patients had to be prescribed fingolimod. For admission to 
PEARL, patients must have been continuously treated with interferon (Avonex®, Beta-
feron®, Extavia®, Rebif®) or glatiramer acetate (Copaxone®) for at least 30 days. DMTs 
had to be prescribed independently of study participation. Furthermore, informed con-
sent had to be given prior to study inclusion. There were no exclusion criteria except for 
the contraindications mentioned in the respective summary of the treatment information. 
Sample sizes in PANGAEA and PEARL were calculated in order to obtain representative 
data on the most commonly prescribed DMTs (BRACE and fingolimod). Furthermore, 
geographical representativeness was ensured by the regional distribution of participating 
practices and centers.  
2.4 Ethical considerations 
The PROs and clinical outcome measures evaluated in the analysis were obtained ex-
clusively from the PEARL and PANGAEA. Prior to study inclusion, informed consent to 
participate and to pass on their pseudonymized data was obtained from patients. Data 
were collected in the presence of a physician or a medical assistant at the MS centers 
and practices. The persons involved in the evaluation had no access at any time to in-
formation that could have violated the anonymity of the study participants. The studies 
were financed by Novartis Pharma GmbH and voted positively by the Ethics Committee 
of the University of Dresden. PANGAEA and PEARL are registered as a non-interven-
tional studies under CFTY720DDE02 and CNVF233ADE08, respectively (VFA, 2010; 




2.5 Data management 
Data of PANGAEA and PEARL were initially available in sas7bdat format in several data 
sets, each referring to one questionnaire, so that UKNDS, PRIMUS, TSQM-9, EQ-5D, 
PRIMUS-A, PRIMUS-L and consumption of resources were separated. The databases 
were structured horizontally, with each row representing one observation. Using the Sta-
tistical Package for Social Science (SPSS) function "merge files”, I combined the sepa-
rated data sets. The variables “Internal_Patient_ID” and “Visit_ID” were used as identifi-
cation criteria for the doubtless merger of the data. 
Whenever possible, the Multiple sclerosis documentation system 3D (MSDS3D) was 
used to ensure the highest possible data quality (Haase et al., 2018b). Additionally, all 
values were checked for plausibility using descriptive statistics. For variables with im-
plausible maximum and minimum values, ranges were defined that resulted from the 
possible range of the observation period. For example, a resource used daily could be 
used a maximum of 92 times in a three-month period. Values outside this range were 
treated as absent. 
Statistical methods for imputation of missing values were not used. Missing values were 
only replaced for binary questions, if the actual value could be derived beyond doubt 
from the answer. When asked about the amount of an occupational disability pension, 
no value was entered for subjects without such a pension during data collection. These 
fields were manually set to zero. The same procedure was used for the question of the 
number of visits to the doctor: if a patient indicated that he had visited a doctor in the last 






The following chapters are excerpts of manuscripts submitted to or published in peer 
review journals:  
 Chapters 3.1 and 3.2 are based on an article titled “Multiple Sclerosis Health Re-
source Utilization Survey (MS-HRS): Development and Validation Study” by 
Ness et al. (2020a). 
 Chapter 3.3 is based on an article titled “Differentiating societal costs of disability 
worsening in multiple sclerosis” by Ness et al. (2019a).  
 Chapter 3.4 is based on an article titled “Real-World Evidence on the Societal 
Economic Relapse Costs in Patients with Multiple Sclerosis” by Ness et al. 
(2020b). 
 
3.1 Questionnaire development and validation 
3.1.1 Development process 
A German expert group consisting of neurologists, healthcare administrators, psycholo-
gists and MS nurses developed the first version of the Multiple Sclerosis Health-resource 
Utilization Survey (MS-HRS) at the University Hospital Dresden in 2009. Following in-
tensive feedback from physicians, nurses and patients, a second more time-efficient ver-
sion was created in 2016. The current adaptive version of the MS-HRS in its German 
and translated English version is in line with the recommendations on the core elements 




3.1.2 Identification of resource consumption 
Relevant resources were identified from the societal perspective. Costs were catego-
rized into direct medical (inpatient stays, day admissions (outpatient), physician consul-
tations, examinations, over-the-counter (OTC) medication, medical consumables and 
professional care), direct non-medical costs (informal care, investments/ purchases) as 
well as indirect costs. Within indirect costs, I considered absenteeism, either short term 
(sick leave) or long-term (disability pension), but also presenteeism, which refers to im-
paired performance during work. (Figure 5).  
 
Figure 5: Identified direct and indirect cost items for patients with MS.  
Reproduced without modifications from Ness et al. (2019b). 
 
Information on resource consumption were obtained from studies, guidelines, textbook 
knowledge, administrative and accounting data and expert opinions (Fowler, 1995; 
Fowler and Floyd, 1993; Kobelt et al., 2006b; Reilly et al., 1993). Within the expert group 
it was decided which resource items are both relevant and nontrivial in magnitude (Luce 
et al., 1996). Keeping multiple use cases in mind, I divided the tool in a core and an 
additional set of items. Core elements are constitutive for the health-resource utilization 
model and sufficient to capture the scope of resource utilization whereas the additional 




Domain Items Valuation 
Direct medical costs 
Inpatient care/ 
day admission 






Visits at general practitioners, neurologists, 
others specialist (Urologists, ophthalmologists, 
psychiatrists), MS-nurses, physical therapists, 
psychologists, occupational therapists, opti-
cians, speech therapists, acupuncturists and 





MRI, CT, spinal tap, blood test, others Physicians' Fee 
Schedule16 
OTC medication Medication, recommending doctor  Patient reported 
Disease-modify-
ing therapies 




Home help and 
support of profes-
sionals 






Medical consumables Patient reported 
Direct non-medical costs 
Investments, 
equipment 
House and car modifications, walking aids, 
wheelchair (manual, electric), scooter, sickbed, 
others, payer, grants 
Patient reported 
Informal care Time taken for preparation of meals, climbing 
stairs, personal care, administration of drugs, 







Full or part time work, sick leaves, reduced 





Absence hours (MS, others), total working 
hours, productivity scale 
Human capital ap-
proach 
Table 8: Core Items of the MS-HRS. 
Abbreviations: over-the-counter (OTC), magnetic resonance imaging (MRI), computed tomogra-
phy (CT). 
Reproduced with layout modifications from Ness et al. (2020a). 
3.1.3 Quantification of resource consumption 
I used the most accurate method of micro-costing defined as “direct enumeration and 
costing out of every input consumed in the treatment of a particular patient” to quantify 
resources (Raftery, 2000). Recall periods of resource utilization have been determined 
to avoid over- and underreporting. I considered that longer recall periods lead to tele-
scoping effects in which events that occurred outside the time frame are mistakenly in-
cluded in the intended period (Stull et al., 2009). Furthermore, I took into account that 
more frequent events and those that are less salient, are less likely to be recalled accu-
rately over a long time span. In conclusion, the recall period may differ with respect to 
the nature of the cost item but should never exceed twelve months. It is noticeable that 
29 
 
unified recall periods across all items of the survey made the questionnaire more intelli-
gible for patients. In the results, I reported all calculated costs as per quarter. 
 
3.1.4 Valuation of resource consumption 
Evaluations conducted from the societal perspectives are intended to reflect the societal 
opportunity costs, which are equal to market prices on perfectly competitive markets. 
Nevertheless, markets in the healthcare sector are imperfect due to statutory regulations. 
Hence, societal opportunity costs have to be estimated in most cases. Bock et al. (2015) 
approximated societal opportunity costs based on published accounting data of individ-
ual actors in the health care system or on regular publications of official statistics. These 
data were used wherever available. An overview of all direct (non-)medical and indirect 
resource items is given in table 9.  
Due to a lack of data, few valuations were calculated from existing values. Visiting a 
nurse was rated with the lowest monetary value of 16.42€. Furthermore, a psychologist 
contact was monetarily valued as visiting a psychotherapist. The valuation for other spe-
cialists (e.g. psychiatrist, urologist, and optician) was calculated as the mean of the given 
examples. Societal opportunity costs for investigations were approximated from the Phy-
sicians' Fee Schedule (KBV, 2011). 
Indirect costs (absenteeism, early retirement, presenteeism) were valued using the hu-
man capital approach (van den Hout, 2010). Absenteeism was defined as not showing 
up for work while presenteeism refers to reduced work productivity due to health prob-
lems. For short term absence (sick leave), I multiplied the average daily working hours 
with the average labor costs in Germany (29.90€/h) (Bock et al., 2015). Data for this 
calculation were obtained from the Federal Bureau of Statistics (BPB, 2011; IAB, 2011).  
 
1406.2  working hours (2011)
233 working days
∗ 29.90€  ℎ𝑜𝑢𝑟𝑙𝑦 𝑠𝑎𝑙𝑎𝑟𝑦 (2011) (II) 
 
For long term absence (disability pension), I multiplied the average daily labor costs 
(127.38€/day) with the average number of working days (233 days) and the disability 
percentage (0-100%) leading to a maximum amount of 29,656.76€ per year.  
To value direct non-medical informal care I used the opportunity cost method. The infor-
mal caregiver’s forgone benefits were approximated by multiplying the hours spent on 
informal care by the opportunity costs of leisure time (21.09€/h). The maximum of hours 




To ensure the comparability of cash flows, prices from different periods were adjusted to 
the 2011 price level using harmonized consumer price index published by the Federal 
Statistical Office as recommended for Germany (IQWIG, 2017). This applies to patients' 
self-reported medication, investments, medical consumables and DMTs. Consumption 
of remaining resources was valued with prices from the year 2011 in order to generate 
comparable costs within the validation population.  
 
Domain  
(# of questions)  Valuation 
Domain  
(# of questions)  Valuation 
Direct medical costs    
Inpatient acupuncturists  18.24€ 
Hospital 593.04 € other alternative  
healing methods 
27.40€ 
Rehabilitation 121.85 € Investigations/ diagnostics 
Nursing 69.80 € (MRI) 120.21 € 
Outpatient  CT 73.78 € 
Hospital 385.48 € Lumbar puncture 38.90 € 
Rehabilitation 46.68 € Blood tests 1.10 € 
Nursing 46.15 € Others 60.66 € 
Ambulant consultations OTC medication Patient reported 
General practitioner 20.06 € Disease modifying 
therapy 
Table 10 
Neurologist 44.72 € Medical consumables Patient reported 
Other specialists 34.73 € Home Help/ profes-
sional care 
27.57 € 
Nurse 16.42 € Direct non-medical costs 
Physiotherapist 16.42 € Equipment, aids, 
modifications 
Patient reported 
Psychologist 78.08 € Informal care 21.09 € 
Occupational thera-
pist 
37.51 € Indirect costs 
Optician 34.78 € Sick leave 127.38 € 
Speech therapists 38.59 € Disability pension (full year) 
29,656.76 € 
Table 9: Valuation of resource costs applied in the MS-HRS (price year 2011). 
Abbreviations: over-the-counter (OTC), magnetic resonance imaging (MRI), computed tomogra-
phy (CT). 






To calculate annual costs for DMTs, I used Defined Daily Dose net-costs multiplied by 
365 days (Zeller, 2012). Net costs account for statutory manufacturer discounts as well 
as pharmacy discounts. Table 10 lists pharmaceutical prices for BRACE therapies, 
Gilenya and Tysabri for the years 2010-2017.  
 







































































































Table 10: Defined Daily Dose net costs in the respective years for DMTs multiplied with 365.  
If no information was available, the last known prices were adjusted with the consumer price in-
dex. All prices in Euro. 
Abbreviations: Disease modifying therapies (DMTs), Betaferon® (BET), Rebif® (REB), 
Avonex® (AVO), Copaxone® (COP), Extavia® (EXT), Gilenya® (GIL) and Tysabri® (TYS). 
a as listed in the technology assessment report (Novartis, 2011). 







3.2 Assessment of psychometric properties 
3.2.1.1 Practicability and reliability 
Practicability was determined by the response rate of patients completing the MS-HRS. 
In addition, I compared characteristics of completers vs. non-completers to avoid selec-
tion bias. For reliability and validity analyses, I focused on the core elements of the sur-
vey (Table 8). As I did not intend to evaluate DMTs at this step, costs for DMTs are not 
part of methodological evaluation. 
For reliability analysis, I estimated test-retest reliability of the total costs in a group of 
stable patients over three months. Stable patients were defined as not having a relapse 
or increase of the EDSS during the three-month retest period and another three months 
prior to the assessment. Thresholds for intraclass correlation coefficient (ICC) were ap-
plied as recommended (ICC < 0.5: poor reliability; 0.5 ≤ ICC < 0.75: moderate; 0.75 ≤ 
ICC < 0.9: good; ICC >0.90: excellent) (Koo and Li, 2016). Guttman’s Lambda-2 and 
Lambda-6 will be reported for the monetarized-standardized items of health-resource 
utilization model with respect to the heterogeneous structure providing a lower bound 
estimate of the consistency of the pricing approach. In an ordinary setting for test con-
struction, desired levels would lay above 0.7. Since the survey is not based on latent 
constructs but instead on real costs, consistency analysis is not part of the primary eval-




Repeated expert consensus meetings of health economists, psychologists and neurolo-
gists were conducted to secure face validity in terms of consistency and completeness. 
Construct validity was assessed as convergent and discriminant validity via correlations 
with associated patient-reported outcomes (PROs) and known-groups analyses by 
EDSS (ranges: 0-1.0; 1.5-2.5; 3.0-4.0; 4.5-5.5). The selected PRO measures were the 
EQ-5D, the UKNDS and the PRIMUS (Doward et al., 2009; Graf von der Schulenburg et 
al., 1998; Greiner et al., 2005; Sharrack and Hughes, 1999). I expected to find signifi-
cantly higher costs in groups with higher EDSS scores and correlations above 0.40 for 
convergent validity. As I did not intend to evaluate DMTs, the TSQM should present 
correlations clearly below 0.3 for discriminant validity (Atkinson et al., 2005). An overview 





cepts Definition Analysis 
Practicability Response rate of persons completing the questionnaire (DeVon et al., 2007) Response rate 
Test-retest relia-
bility 
Temporal stability of a test from one measure 







The instrument encompasses all items to rep-





Degree to which an instrument measures the 
construct it is intended to measure (DeVon et 
al., 2007). 
Convergent validity 
Correspondence between constructs that are 
theoretically similar (DeVon et al., 2007). 
 
Discriminative validity 
Capability to differentiate between constructs 
that are theoretically similar (DeVon et al., 
2007). 
Correlation tests 
Table 11: Validity and reliability measurements assessed for the MS-HRS. 




3.3 Definition of clinical outcome measures 
Changes in disability were assessed at a regular basis using the EDSS every six months 
during clinical visits. CDW measured by EDSS was defined as: ≥1.5-point increase for a 
reference-score of 0; ≥1-point increase for a reference-score 1.0-5.0; and ≥0.5 point in-
crease for a reference score greater than 5.5. Due to its higher sensitivity, I implemented 
a roving reference score instead of a fixed baseline reference score to detect CDW 
(Kappos et al., 2018a). A roving EDSS score is independent of the baseline so that EDSS 
assessments at baseline, months six or twelve can be applied as reference. Increase in 
EDSS and confirmation of the increase can take place ≥6 and ≥12 months apart from 
the reference score, respectively. In order to have sufficient data to determine CDW and 
in accordance with earlier studies patients with at least three EDSS assessments were 
included (Lorscheider et al., 2016). 
CDW events in which no relapse occurred between reference and confirmation assess-
ment were declared as PIRA (Figure 6). If a relapse occurred between reference and 
confirmation assessment, the event was classified as RAW. Furthermore, I distinguished 
RAW from RWW applying to patients, who recover from relapses without having an in-
crease in accumulated disability as defined by CDW. Patients achieving freedom of re-
lapse activity and CDW were defined as DAF. Relapses were assessed every 3 months 
according to the clinical judgement of physicians during routine clinical visits. 
 
Figure 6: Schematic of the assessment of clinical descriptors. 
A roving EDSS reference score was used to detect CDW-6 events within two years. CDW-6 
was defined as increases in EDSS of ≥1.5 points for reference score between 1.0-5.5 or ≥0.5 
points for reference score ≥6.0. Physicians assessed EDSS and relapses every six and three 
months, respectively.  
Reproduced without modifications from Ness et al. (2019a).  
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3.4 Assessment of relapse associated costs 
Patients were considered as ‘relapse active’ if they had at least one relapse during the 
two-year follow-up whereas ‘relapse inactive’ refers to patients without relapses during 
the follow-up time. I calculated relapse costs as the cross-sectional difference in mean 
quarterly costs between relapse-active patients during relapse quarters and relapse-in-
active patients. For the relapse costs analysis, I applied a propensity score (PS) match-
ing to compensate for differences between relapse active and relapse inactive patients. 
Patients were matched in a 1:1 ratio using a nearest neighbor matching. PS were calcu-
lated as the probability to be part of the relapse active group according to the following 
baseline predictors: EDSS score, time since diagnosis of MS, disease-modifying thera-
pies (DMT), age and gender. These variables were selected for matching as previous 
studies showed that a shorter disease duration and lower EDSS are associated with 
higher relapse activity, that women tend to experience more relapses (Kalincik, 2015). 
Furthermore, DMTs are associated with a varying effectiveness in reducing relapse rate 
(Li et al., 2019). 
In addition to the cross-sectional approach of calculating relapse costs, I analyzed re-
lapse associated costs longitudinally. Each relapse follow-up was re-baselined and costs 
for corresponding intervals before (prior relapse) and after this interval (post relapse) 
were calculated additionally (Figure 7). On an intraindividual basis, I calculated the dif-
ference between quarterly costs prior relapse and quarterly cost during relapse. For the 
analyses, I excluded 77 persons who had less than three visits. The excluded persons 
did not statistically significant differ in their sociodemographic or disease characteristics. 
Relapse associated costs are additionally reported stratified by body mass index (BMI). 
The BMI was determined by weight and height of the patients and classified as under- 
and normal weight (<25 kg/m2), overweight including pre-obesity (25 kg/m2-30 kg/m2) 





Figure 7: Assessment of changes in resource utilization (prior-, during and post-relapse). 
Abbreviations: MS- Health Resource Survey (MS-HRS). 
3.5 Statistical analyses 
Continuous values were reported as arithmetic means and standard deviations (SD, ±). 
Ordinal values were described by median interquartile range (IQR) and nominal values 
as percentages (%).  
For the validation of the questionnaire, one-way random ICC were used to calculate es-
timates for the test-retest reliability. All other correlations were calculated as Spearman's 
rank correlation coefficient. Kruskal-Wallis-H-tests were conducted for known group 
analyses. Mann-Whitney-U-tests with adjustments by the Bonferroni correction for mul-
tiple tests were applied for pairwise comparisons. 
Statistical analyses of healthcare resource use and cost data has several challenges. 
The data are often skewed, can have multimodal distributions and heavy tails (Mihaylova 
et al., 2011). To take care of these issues I applied a Generalized Linear Mixed Models 
(GLMM) with a negative binomial distribution and a log link function for model-based 
analysis with monetary outcomes.  
The influence of PIRA and RAW on (i) total costs excluding DMTs, (ii) direct medical 
costs excluding DMTs, (iii) direct non-medical costs and (iv) indirect costs were reported 
through incidence rate ratios (IRR) and corresponding 95% confidence intervals (95% 
CI). For example, an IRR of 1.5 indicates that a specific group had a 50% higher quarterly 
resource consumption averaged over two years and compared to patients that were re-
ferred to as achieving DAF, while holding the other variables constant in the model. Pa-
tients achieving DAF served as the reference group for PIRA and RAW in the statistical 
models. Multivariate models were adjusted for sex, age, EDSS, data source and time, 
which indicated the sequence of assessments per patient.  
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Statistical differences in relapse costs between patient and disease strata were derived 
from Generalized Linear Models (GLM) with a negative binomial distribution and the re-
spective cost category as the dependent variable. The models included the characteristic 
(gender, age, BMI, disease duration, EDSS or therapy) of interest as well as a variable 
indicating the relapse status (relapse active vs. relapse inactive) and the interaction of 
both. For example, to assess statistical differences in total relapse costs regarding dis-
ease duration, we included the disease duration variable, the variable indicating the re-
lapse status and the interaction of these two variables as independent variables.  
All reported p-values were compared to an alpha-error level of 5%. No imputations were 
made for missing values. Statistical analyses were performed using SPSS statistics for 





The following chapters are excerpts of manuscripts submitted to or published in peer 
review journals:  
 Chapters 4.1 is based on an article titled “Multiple Sclerosis Health Resource 
Utilization Survey (MS-HRS): Development and Validation Study” by Ness et al. 
(2020a). 
 Chapter 4.2 is based on an article titled “Differentiating societal costs of disability 
worsening in multiple sclerosis” by Ness et al. (2019a). 
 Chapter 4.3 is based on an article titled “Real-World Evidence on the Societal 
Economic Relapse Costs in Patients with Multiple Sclerosis” by Ness et al. 
(2020b). 
4.1 The Multiple Sclerosis Health Resource Survey 
4.1.1 Study population  
In total, 2207 of 2388 patients completed the questionnaire at baseline and were there-
fore included in the validation process. The population was in average 41.73 years old 
and was mostly female (73.10%) (Table 12). Employed patients (61.76%) were working 
predominantly full time (60.79%). 
In terms of relapses within the previous year, active (54.96%) and non-active (45.05%) 
patients were balanced in the population. Participants reported an average disease du-






Female gender (n (%)) 1609 (73.10) 
Age (mean±SD) 41.73±10.19 
Education 
 
   intermediate/ advanced school-leaving 
certificate 
439 (20.92) 
   vocational training/ university degree 1410 (67.21) 
   Other 249 (11.87) 
Employment 
 
   percentage employed 1347 (61.76) 
   percentage full time 814 (60.79) 
Disease Characteristics 
Number of relapses in previous year, n (%) 
 
   0 1192 (54.96) 
   1 612 (28.22) 
   2 267 (12.31) 
   >=3 98 (4.52) 
Duration of disease since diagnosis, years 
 
   mean±SD 7.54±6.11 
   median (IQR) 6.00 (3.00, 11.00) 
EDSS score 
 
   mean±SD 2.43±1.57 
   median (IQR) 2.00 (1.00, 3.50) 
Table 12: Baseline characteristics of the study population included in the validation process 
(N=2207). 
Reproduced with layout modifications from Ness et al. (2020a). 
 
4.1.2 Validation of the questionnaire 
4.1.2.1 Practicability 
Overall, 2207 out of 2388 patients completed the questionnaire (response rate: 92.40%).  
Therefore, the answers of 2207 patients could be used to calculate total costs and all 
other parts of the health-resource model. Non-completing patients (n=181) did not differ 
in their gender distribution, age or EDSS score, but presented a slightly longer disease 








Female gender (n (%)) 1609 (73.10) 127 (70.90) 
Age (mean±SD 41.73±10.19 41.06±9.98 
Duration of disease since diagnosis, 
years 
  
   mean±SD 7.54±6.11 9.67±7.21 
   median (IQR) 6.00 (3.00, 11.00) 8.00 (1.00, 19.00) 
EDSS score   
   mean±SD 2.43±1.57 2.68±1.73 
   median (IQR) 2.00 (1.00, 5.50) 2.00 (1.00, 5.50) 
Table 13: Comparison of baseline characteristics of included and excluded patients for the vali-
dation process. 
4.1.2.2 Reliability 
I assessed the reliability mainly as test-re-test reliability in a stable subgroup of patients. 
Overall, 1192 of 2207 (54.0%) patients fulfilled the criteria of presenting a stable MS 
within that period. The ICC for that group was 0.828 over a course of three months. 
In addition, Guttman’s Lambda-2 (λ2=0.679) and Lambda-6 (λ6=0.694) indicated an ac-
ceptable consistency between the standardized monetarized items of the health-re-
source model (excluding DMT costs). 
 
4.1.2.3 Validity 
I analyzed the construct validity for total costs of the MS-HRS via known-groups (exclud-
ing DMT costs). In all four EDSS groups, I found significantly different MS-related total 
costs and sub costs (Table 14). Further, all pairwise comparisons indicated significant 



















































Table 14: Direct (non-)medical and indirect costs (excl. DMTs) stratified by EDSS scores.  
Costs differed significantly between EDSS strata. 
Reproduced with layout modifications from Ness et al. (2020a). 
 
 
Convergent validity analyses showed that total costs correlated positively with an in-
creased (patient-reported) disability (UKNDS sum score: r=0.411), the lost ability to par-
ticipate in daily routines and activities (PRIMUS Activities: r=0.423) and negatively with 
health-related quality of life (HRQoL; PRIMUS QoL: r=0.350; EQ-5D: r=-0.342) (all 
p<0.001). 
For discriminant validity, correlations of total costs with TSQM scores ranged from -0.006 
(convenience) to -0.216 (effectiveness). As expected, the inclusion of DMT costs lowered 
the correlations with all PROs (by 0.07 on average) but the relations between correlations 












Convergent validity   
UKNDS sum score 0.411 0.348 
PRIMUS activity 0.423 0.346 
Primus Quality of life 0.350 0.290 
EQ5D -0.342 -0.274 










Table 15: Correlation coefficients for convergent and discriminant validity. 





4.1.3 Resource utilization 
The majority of patients stated that they used direct medical services in the past three 
months. In contrast, less than every second patient (44%) caused indirect medical costs 
and 16% claimed direct non-medical costs. Besides DMTs, indirect costs were the main 
cost drivers ahead of direct medical and direct non-medical costs. 
Patients were mainly treated in outpatient practices (85%) and less often during inpatient 
hospital stays (6%) and daycare admissions (3%). Among the direct medical costs, in-
patient treatment caused the highest costs (315.06€±1587.09€), followed by consulta-
tions in the primary sector (209.87±292.73€) and day admissions in hospitals 
(32.22€±311.68€). Total costs per quarter averaged on 2462±3650€ (median: 631€) 
without DMTs and 7126€±3697€ (median: 5871€) including DMTs. Therefore, annual 
costs of a mild to moderate RRMS ranged between 9528±14,603€ (without DMTs) and 
28,203±14,808€ (with DMTs) (Table 16). 




2068 (93.70%) 601.30±1708.55 174.00 (75.00, 
417.50) 
Inpatient care 138 (6.25%) 315.06±1587.09 0.00 (0.00, 0.00) 
Day admission 65 (2.95%) 32.22±311.68 0.00 (0.00, 0.00) 
Consultations 1817 (82.33%) 209.87±292.73 109.50 (44.72, 
268.32) 
Examinations 1429 (64.75%) 32.34±35.63 30.05 (0.28, 45.77) 
OTC Medication 693 (31.40%) 15.02±46.43 0.00 (0.00, 10.00) 
Professional care 115 (5.21%) 7.02 (44.79) 0.00 (0.00, 0.00) 
Disease modifying 
therapies 




352 (15.95%) 44.65±229.51 0.00 (0.00, 0.00) 
Investments 38 (1.72%) 9.14±165.80 0.00 (0.00, 0.00) 
Informal care and 
community service 
337 (15.27%) 37.25±158.57 0.00 (0.00, 0.00) 
Indirect costs 977 (44.27%) 1816.50±2880.74 0.00 (0.00, 
3037.00) 
Short-term absence 320 (14.50%) 441.53±1782.18 0.00 (0.00, 0.00) 
Disability pension 352 (15.95%) 852.98±2062.98 0.00 (0.00, 0.00) 
Presenteeism 475 (21.52%) 522.00±1333.18 0.00 (0.00, 0.00) 
Table 16: Health resource utilization in persons with MS per quarter (N=2207). 
Abbreviation: over-the-counter (OTC). 




4.2 Societal economic impact of disability worsening 
4.2.1 Study population 
In total, 1959 patients had an EDSS score <6 and were therefore included to analyze the 
economic impact of disability worsening. Patients reported an average age of 
41.62±10.04 years and were mostly female (72.82%). The mean disease duration of the 
total population was 7.30±5.95 years with a baseline mean EDSS value of 2.26±1.37. In 
terms of relapses in the year before baseline, patients were balanced between active 
(43.56%) and inactive (56.44%).  
Of the total population, 985 patients (50.28%) were classified achieving DAF status after 
two years, 166 (8.47%) fell in the group PIRA, 150 (7.66%) into RAW and 407 (20.78%) 
had RWW (Table 17). Due to an insufficient number of EDSS assessments, 251 
(12.81%) patients did not meet the definition of any aforementioned groups. For all sub-
sequent analyses, these patients were summarized under the label “others”. 
PIRA patients were older (44.48±9.80 years of age) and longer affected by the disease 
(8.48±7.13 years) compared to the other groups of interest. Furthermore, the rate of 
women was highest in patients with RAW (78.67%).  
In the year prior baseline, patients grouped in RAW and RWW were significantly more 
often relapse-active (51.68% and 57.18%, respectively) than patients with PIRA 
(30.91%) (p<0.001). 
Nearly two third (62.17%) of all patients were employed at baseline with the lowest rate 
reported for PIRA patients (57.23%). RAW and RWW patients had a higher sick leave 













    
Female gender (n (%)) 1425 (72.82) 689 (70.02) 115 (69.28) 118 (78.67) 








18-29 years (n(%)) 271 (13.83) 125 (12.69) 13 (7.83) 22 (14.67) 
30-49 years (n(%)) 1233 (62.94) 624 (63.35) 96 (57.83) 90 (60.00) 
50 years and older 
(n(%)) 
455 (23.23) 236 (23.96) 57 (34.34) 38 (25.33) 
Patients in working age 
(n(%)) 
1920 (98.01) 965 (97.97) 162 (97.59) 147 (98.00) 
Employed (n(%)) 1218 (62.17)  624 (63.35) 95 (57.23) 92 (61.33) 
Employed at full time 
(n(%)) 
722 (36.86) 385(39.09) 58 (34.94) 54 (36.00) 
Employed with sick 
leave (past 3 months) 
(n(%)) 
265 (13.53) 101 (10.25) 17 (10.24) 26 (17.33) 
Employed with disabil-
ity pension (n(%)) 
289 (14.75) 136 (13.81) 28 (16.87) 31 (20.67) 
Not living alone (n(%)) 1494 (81.42) 746 (80.56) 123 (79.87) 109 (80.74) 
Disease Characteris-
tics 











EDSS (mean±SD) 2.26±1.37 2.15±1.39 2.16±1.30 2.17±1.32 
EDSS<4 (n(%)) 1613 (82.34) 814 (82.64) 143 (86.14) 128 (85.33) 
EDSS≥4 (n(%)) 346 (17.66) 171 (17.36) 23 (13.86) 22 (14.67) 
At least one relapse 
prior to baseline (n(%)) 
849 (43.56) 352 (35.85) 51 (30.91) 77 (51.68) 
Table 17: Baseline characteristics of the study population for the analysis of associations be-
tween disability worsening and societal economic costs (N=1959). 




4.2.2 Descriptive cost analyses 
Total mean annual costs (inclusive DMTs) amounted to 27,958€±10,139€ per patient, 
which corresponds to quarterly costs of 6929€±2886€, averaged over a mean follow up 
time of 20.68±6.07 months. Excluding DMTs, overall mean quarterly costs were 
2029€±2765€. Indirect costs accounted for 83.7% (1699€±2444€) of resource utilization, 
followed by direct medical costs (14.59%; 296€±888€) and direct non-medical costs 
(1.72%; 35€±214€) (Table 18). The proportion of patients claiming resources in two 
years varied within cost categories: While 97.35% of the patients utilized at least once 
direct medical resources (without DMTs), 25.54% used resources leading to direct non-
medical costs and 73.46% affirmed causing indirect costs. 
Female patients utilized slightly more resources compared to males. Total societal costs 
increased with age from an average of 984€±1922€ for patients younger than 30 years 
to 2519€±2933€ for patients older than 50 years significant (p<0.05), mainly due to 
higher expenditures for indirect and direct medical costs.  
A significant monetary difference occurred in all cost categories between patients with 
mild (1707€±2536€) and moderate disability (3556€±3254€) (p<0.001). This was mainly 
due differences in indirect costs (3010€±2877€ (EDSS <4) vs. 1423€±2248€ (EDSS≥4)). 
PIRA patients consistently incurred higher costs (2391€±2897€) compared to stable pa-
tients achieving DAF (1703€±2489€) (p<0.001). RAW status led to highest total resource 
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Table 18: Mean±SD quarterly cost in Euro (€) within two years of study time (N=1959). 
Reproduced with layout modifications from Ness et al. (2019a).  
 
4.2.3 Associations between disability worsening and costs 
PIRA caused on average 29% higher total costs compared to patients achieving DAF 
status after controlling for the effects of increased disability, age and female gender 
(IRR=1.29, 95% CI 1.08-1.53, p<0.05) (Figure 8). The effect of PIRA was most striking 
in direct medical costs. These were factored by 1.48 (95% CI: 1.13-1.95, p<0.01) com-





Figure 8: Effects (IRR, 95% CI) of PIRA and RAW on the quarterly economic costs compared to 
DAF.  
Results were adjusted for age, gender, EDSS, time and data source.  
Abbreviation: Progression independent of relapse activity (PIRA); Relapse associated worsen-
ing (RAW); Disease activity free (DAF). 
*:p<0.05; **:p<0.01 
Reproduced without modifications from Ness et al. (2019a).  
 
In comparison to PIRA, the effect of RAW was stronger in all cost categories. Total costs 
increased by factor 1.56 (95% CI: 1.30-1.87, p<0.001) in comparison to stable patients. 
Direct medical costs increased by factor 2.25 (95% CI: 1.72-2.94, p<0.001) and indirect 
costs by factor 1.43 (95% CI: 1.17-1.75, p<0.001) compared to patients achieving DAF. 
For both, PIRA and RAW, the increases in direct medical costs were in particular due to 
higher rates of inpatient and outpatient hospitalizations (Figure 9). 
These findings support the first hypothesis that societal economic costs are significantly 





Figure 9: Comparison of patients with in- and outpatient hospitalizations within two years.  





















4.3 Societal economic impact of relapses 
4.3.1 Study population 
Out of 1959 principal eligible subjects, we excluded 77 persons who had less than three 
visits so that 1882 patients were included in the analysis. Of these, 607 (32%) presented 
at least one relapse, while 1275 (68%) patients were free of relapse activity during the 
two-year study period (Table 20). Compared with relapse inactive patients, relapse ac-
tive patients were younger (40.46±9.98 vs. 42.09±10.01, p<0.01), more often female 
(76% vs. 70%, p<0.01), more severely disabled (2.41±1.30 and 2.17±1.39, p<0.001) and 
more often employed (64% vs. 62%, p=0.712). The cohorts did not differ in BMI with 
average scores of 25.45±5.14 and 25.66±5.11 between the relapse inactive and relapse 
active population, respectively. After PS matching, 597 out of 607 patients per cohort 
were retained for further analysis. The PS matching resulted in an alignment of the re-
lapse inactive to the relapse active population (Figure 10 and Figure 11). There were no 
statistically significant differences between the matched cohorts (Table 20). One quarter 
(25%) of the relapse active patients presented with RAW.  
 




Female gender (n (%)) 1360 (72.30) 65 (85.53) 
Age (mean±SD) 41.56±10.03 42.73±10.40 
Duration of disease since diagnosis, 
years 
  
   mean±SD 7.29±5.95 7.55±5.83 
   median (IQR) 6.00 (3.00, 12.00) 6.00 (3.00, 11.00) 
EDSS score   
   mean±SD 2.25±1.36 2.53±1.40 
   median (IQR) 2.00 (1.00, 3.50) 2.50 (1.50, 4.00) 
Table 19: Comparison of baseline characteristics of included and excluded patients for the re-


































(n(%))) 492 (39) 266 (44)   248 (42) 257 (43)   
30-49 years 
(n(%)) 464 (36) 225 (37)   215 (36) 224 (38)   
50 years and 



















334 (27) 159 (27)   164 (29) 157 (27)   
Obesity (BMI 


























0-1.5 (n(%)) 519 (41) 185 (30)   179 (30) 185 (31)   
2.0-3.5 (n(%)) 535 (42) 320 (53)   316 (53) 312 (52)   




          <0.001
 a 
Yes (n(%)) 0 (0) 150 (25)   0 (0) 149 (25)   
No (n(%)) 1275 (100) 457 (75)   
597 
(100) 448 (75)   
Therapy      0.77 
BRACE (n(%)) 958 (75) 493 (81)   479 (80) 483 (81)   
Fingolimod 
(n(%)) 
317 (25) 114 (19)   118 (20) 114 (19)   
Table 20: Characteristics of the study population for the analysis of relapse associated societal 
economic costs (N=1882). 
a P-values were derived from Chi Square test. 
b P-values were derived from Mann-Whitney U test. 





Figure 10: Love plot summarizing the covariate balance before and after PS matching.  
All covariates were balanced using PS matching. The vertical line represents the threshold 
within balance is considered to be achieved.  






Figure 11: Histogram comparing the density of PS before and after matching.  
Reproduced without modifications from Ness et al. (2020b). 
 
4.3.2 Relapse associated costs  
The relapse active cohort incurred significantly higher costs during relapses compared 
to the inactive cohort (p<0.001) (Figure 12). More specifically, total relapse costs 
amounted to 1253€ consisting of 556€ (44%) direct and 697€ (56%) indirect costs. Dif-
ferences in direct costs arose essentially from inpatient treatment (relapse inactive: 93€ 
vs. relapse active: 497€) day admissions (relapse inactive: 9€ vs. relapse active: 75€) 
physician consultations (relapse inactive: 152€ vs. relapse active: 232€) while costs of 
absenteeism (relapse inactive: 137€ vs. relapse active: 750€) were mainly responsible 




Figure 12: Resource costs (3 months) for relapse inactive (n=597) and relapse active (RAW: 
n=149; not RAW n=448) patients (before, during and after relapse).  
Relapse costs, defined as the difference in inactive and active patients during relapses, were 
significant (∆ 1253€, p<0.001). A significant increase was also observed between prior relapse 
and during relapse quarter. 
Abbreviations: prior relapse= three months before relapse quarter; during relapse= relapse 
quarter; post relapse= three months after relapse quarter; RAW= relapse associated worsening 
Reproduced with modifications from Ness et al. (2020b). 
 
 
There were noticeable patterns in relapse costs regarding disease and patient charac-
teristics (Table 21). Total relapse costs were higher in patients with shorter disease du-
ration (<5 years: 1729€ vs. >10 years: 758€; p<0.001) and those being mildly disabled 
(EDSS 0-1.5: 1506€ vs. EDSS 4.5-5.5: 987€; p<0.001). In mildly disabled patients and 
those with a short disease duration, indirect relapse costs (range: 971€-1093€) con-
stantly outweighed direct costs (535€-636€). Men incurred higher total relapse costs 
compared to women (1451€ vs. 1193€), which is mostly due to higher indirect work re-
lated relapse costs (920€ vs. 628€). However, differences were not statistically signifi-
cant. Furthermore, patients on fingolimod incurred lower relapse costs throughout all 
cost categories than patients on BRACE therapy (total relapse costs: 1067€ vs. 1296€) 
with noticeable differences in direct relapse costs (316€ vs. 611€). A detailed breakdown 






Mean quarterly costs in 
Euro±SD 
Direct  
Mean quarterly costs in 
Euro±SD 
Indirect 
Mean quarterly costs in 
Euro±SD 












Male (a) 2003±2014 1451 311±474 531 1692±1897 920 
Female 
(b) 2086±2321 1193 351±723 564 1735±2063 628 
Age             
18-29 
(a) 1466±1844 1405c 230±432 686b,c 1236±1707 718 
30-49 
(b) 2319±2278 1437 424±705 505a 1895±2055 932 
50+ (c) 2777±2604 690a 419±919 382a 2358±2296 308 
BMI             
<25 (a) 1880±2213 1029 318±740 465 1562±1963 564 
25-30 
(b) 2317±2295 1510 378±648 720 1938±2086 789 
>30 (c) 2324±2280 1653 386±520 586 1938±2119 1067 
Disease Duration 
<5 years 
(a) 1559±1869 1729b,c 298±519 636 1261±1710 1093b,c 
5-10 
years (b) 2435±2362 713a 373±687 463 2062±2140 250a 
>10 
years (c) 2822±2630 758a 409±928 480 2413±2288 278a 
EDSS 
0-1.5 (a) 806±1203 1506b,c 137±198 535 669±1137 971b,c 
2-3.5 (b) 2310±2126 1239a 367±582 566 1943±1968 672a 
4-5.5 (c) 3528±2849 987a 625±1181 594 2903±2509 393a 
Therapy  
BRACE 
(a) 2055±2252 1296 331±657 611 1724±2045 685 
FINGO 
(b) 2114±2262 1067 387±739 316 1728±1947 751 
Table 21: Total, direct and indirect relapse costs (∆) stratified by patient and disease character-
istics.  
Relapse costs (∆) were defined as the difference in costs between relapse inactive and relapse 
active patients. Letters indicate significant statistical differences (p<0.05) between subgroups. 
P-Values were derived from GLM. The GLM included the respective cost category and covari-
ates as well as a variable indicating the relapse status and the interaction of both.  
Abbreviations: Body mass index (BMI); Beta interferons and glatiramer acetate (BRACE); Fin-
golimod (FINGO). 







Mean quarterly costs 
in Euro (SD) 
Day admissions 
Mean quarterly costs 
in Euro (SD) 
Physician consulta-
tions 
Mean quarterly costs 
in Euro (SD) 
Informal care 
Mean quarterly costs in 
Euro (SD) 
Sick leave 




Mean quarterly costs 








































































































































































































































































Table 22: Detailed breakdown of relapse costs (∆) stratified by patient and disease characteristics . 
Relapse costs (∆) were defined as the difference in costs between relapse inactive and relapse active patients. The table lists resources that were increasingly 
used during relapse periods. Certain resources, such as complementary medicine or direct non-medical investments, are utilized at a lower degree during 
relapse periods compared to relapse-free periods.. 
Abbreviations: BMI= Body mass index; BRACE= Beta interferons and glatiramer acetate; EDSS= Expanded disability status scale 
Reproduced with modifications from Ness et al. (2020b). 
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I assessed relapse costs without PS-matching as a sensitivity analysis. The matched 
and unmatched total relapse cost estimates differed by up to 23% due to the heteroge-
neity in patient and disease characteristics in the respective populations (Table 23).  
 Total Mean quarterly costs in 
Euro±SD 
Direct  
Mean quarterly costs in 
Euro±SD 
Indirect 
Mean quarterly costs in 
Euro±SD 












Male (a) 2001±2150 1453 244±376 599 1758±2031 854 
Female 
(b) 1997±2331 1289 317±648 598 1680±2074 690 
Age             
18-29 (a) 1410±1935 1473 221±526 687 1189±1729 786 
30-49 (b) 2238±2351 1532 335±566 603 1903±2157 929 
50+ (c) 2560±2449 907 352±670 449 2208±2211 457 
BMI             
<25 (a) 1740±2091 1175 265±550 522 1475±1899 654 
25-30 (b) 2190±2397 1632 308±565 796 1882±2193 836 
>30 (c) 2432±2488 1548 393±737 555 2039±2160 993 
Disease Duration 
<5 years 
(a) 1541±2012 1758 258±538 670 1283±1827 1088 
5-10 
years (b) 2218±2322 930 303±569 533 1915±2105 397 
>10 
years (c) 2599±2499 981 353±660 536 2246±2247 445 
EDSS 
0-1.5 (a) 1006±1506 1305 137±211 535 870±1453 771 
2-3.5 (b) 2284±2154 1247 330±500 597 1954±1996 649 
4-5.5 (c) 3640±2861 916 582±1050 648 3058±2512 268 
Therapy 
BRACE 
(a) 1915±2253 1441 287±541 655 1628±2048 786 
FINGO 
(b) 2253±2332 929 321±690 382 1932±2085 547 
Table 23: Sensitivity analysis for relapse costs (∆) stratified by patient and disease characteris-
tics.  
Relapse costs (∆) were defined as the difference in costs between relapse inactive and relapse 
active patients.  
Abbreviations: Body mass index (BMI); Beta interferons and glatiramer acetate (BRACE); Fin-
golimod (FINGO). 
Reproduced with modifications from Ness et al. (2020b). 
 
A higher economic burden for patients with short disease duration and those that are 
mildly disabled was also observed when assessing the increase in resource costs from 
prior relapse to relapse quarter in relapse active patients. However, relapse associated 
costs were lower throughout all subgroups in this predisposed active only population.  
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4.3.3 Longitudinal analysis of relapse associated costs 
In the relapse active cohort, costs increased significantly from prior relapse to the relapse 
period (total 1042€; p<0.001). In detail, direct and indirect costs increased by 527€ 
(p<0.001) and 515€ (p<0.001), respectively. The increase was strongest for inpatient 
stays (+364%, 390€; p<0.001) and day admissions (+241%, 53€; p<0.001) in direct 
costs, while in indirect costs the increase was higher in costs of absenteeism (+127%, 
419€; p<0.001) than in those of presenteeism (+10%, 88€; p=0.002). Costs mostly de-
creased in the post relapse quarter close to the initial level. However, in patients with 
RAW direct costs and costs of absenteeism remained elevated (Figure 13). 
The results presented in chapter 4.3 support the hypothesis that young patients and 
those with a shorter disease duration have higher societal economic relapse costs than 




Figure 13: Quarterly costs (in €) of direct and indirect resource items before during and post re-
lapse.  
Abbreviations: Three months before relapse quarter (prior relapse); Relapse quarter (during re-
lapse); Three months after relapse quarter (post relapse); Relapse associated worsening 
(RAW). 






The following chapters are excerpts of manuscripts submitted to or published in peer 
review journals:  
 Chapters 5.2 is based on an article titled “Differentiating societal costs of disability 
worsening in multiple sclerosis” by Ness et al. (2019a). 
 Chapter 5.3 is based on an article titled “Real-World Evidence on the Societal 
Economic Relapse Costs in Patients with Multiple Sclerosis” by Ness et al. 
(2020b). 
 Chapter 5.4 is based on an article titled “Multiple Sclerosis Health Resource Uti-
lization Survey (MS-HRS): Development and Validation Study” by Ness et al. 
(2020a).  
 
5.1 Summary of results 
There is an urgent need to reduce the societal economic burden in chronic diseases like 
MS. Therefore, I investigated how relapses and disability worsening affect the societal 
economic costs. The results showed that disability worsening is highly associated with a 
substantial societal economic burden. In particular, two-year real-world data revealed 
that not only RAW but also PIRA were associated with a significantly increase in costs. 
Hence, I confirmed the hypothesis that societal economic costs are significantly higher 
in patients with disability worsening compared to patients being free of disease activity. 
Furthermore, I confirmed the hypothesis that younger patients and those with a shorter 
disease duration have higher societal economic relapse costs than older patients and 
those with longer disease duration. This study provides preliminary evidence that delay-
ing disability worsening and preventing relapses should be prioritized in medical research 
to reduce the societal economic burden in patients with MS.  
The analyses provide valuable information about the diverse economic impact of MS and 
thus might help decision makers to allocate scarce resources. Furthermore, in the con-
text of economic evaluation, the results have the potential to increase the validity of cost-
effectiveness assessments of innovative therapies in relapsing MS. Given the large num-
ber of available and upcoming MS therapies of varying effectiveness and costs, eco-




5.2 Societal economic impact of disability worsening 
The economic burden of MS including its direct, indirect and intangible costs has been 
widely examined in cross-sectional analyses (Ernstsson et al., 2016; Naci et al., 2010). 
However, to the best of my knowledge, no previous studies on societal economic costs 
used a longitudinal design comparable to mine. I assigned patients to either clinical DAF, 
PIRA, RAW or RWW through up to five consecutive EDSS and eight relapse assess-
ments and estimated quarterly societal economic costs. I found that RAW and PIRA lead 
to significantly higher societal economic costs than DAF.  
Both, RAW and PIRA led to increased utilization of direct medical resources. Neverthe-
less, the monetary effect was stronger for RAW. The proportion of participants with in-
patient hospitalizations was almost twice as high in RAW compared to PIRA within two 
years. However, the average number of inpatient days did not differ between the groups. 
In contrast, both the proportion of patients with outpatient admissions and the average 
days of outpatient stays in the RAW group were more than twofold compared to the PIRA 
population. Beyond disease activity, I observed further parameters influencing the eco-
nomic burden of MS. Higher age was associated with increased costs. Higher age (≥50 
years) was significantly more frequent in patients with PIRA compared to DAF and RAW, 
which could be explained by the underlying progressive course that preferentially occurs 
at later stages of the disease and thus, in older patients (Lublin et al., 2014). Increased 
mean disease duration for patients with PIRA supports this suggestion. Lastly, total costs 
were slightly higher in female patients compared to their male counterparts. RAW status 
was associated with female gender. This observation can be attributed to the predispo-
sition of relapses in women (Kalincik et al., 2013). To receive valid results, I adjusted the 
multivariate analysis for age, gender, EDSS.  
In the present analyses, 985 patients neither showed disability worsening nor relapses 
(herein defined as DAF), which corresponds to 50.28% of patients. This is in line with a 
comprehensive DAF analysis within a real-world cohort of 306 mild to moderately disa-
bled MS patients in Germany, in which DAF was achieved by 45% of patients after two 
years (Huhn et al., 2019). Although the population I analyzed consisted exclusively of 
patients with RRMS, a substantial proportion of accumulated disability was due to a pro-
gressive clinical course: 8.47% of patients in the study had a PIRA event within two years 
which corresponds to findings from a recent study (7.00%-9.66%) (Kappos et al., 2018b). 
On the contrary, the incidence of RAW was slightly higher in the investigated population 
(7.66% vs. 2.0%-4.7%) which might be explained by differences in the methodology in 
the assessment of RAW events (Kappos et al., 2018b). EDSS baseline scores were 
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comparable between the subgroups. A large number of recent studies conducting re-
search on PIRA and RAW in a clinical context, supporting the validity and importance of 
the approach (Kappos et al., 2018a; Kappos et al., 2018b; Koch-Henriksen et al., 2019). 
 
The mean annualized economic burden including DMTs was 26,482€±9107€ for patients 
with EDSS scores <4. This finding is comparable to results of Flachenecker et al. (2017) 
who found mean annual costs of 28,200€ (EDSS <4; price level 2015) in a German 
substudy with self-assessed EDSS and a multinational survey by Karampampa et al. 
(2012) in which mean annual costs of 25,270€ (price level 2009) were reported for Ger-
many (Flachenecker et al., 2017; Karampampa et al., 2012b). Furthermore, I found a 
cost ratio of 1.32 between EDSS strata (0-3.5 vs. 4-5.5) while Flachenecker et al. re-
ported a cost ratio of 1.56 (Flachenecker et al., 2017). Taking into account that in 
Flachenecker EDSS strata of 0-3.5 and 4.0-6.0 were compared, the ratios can be re-
garded as comparable. I also confirmed that a progressive clinical course increases so-
cietal economic costs as it was stated before (Gyllensten et al., 2019). Nevertheless, I 
found differences in the composition of total costs that depart from those reported in 
literature (Flachenecker et al., 2017). Particularly noticeable are lower expenses for hos-
pital stays, examinations and informal care in this analysis, which could be explained by 
the milder disease profile in this analysis. 
5.3 Societal economic impact of relapses 
Relapse costs have been investigated repeatedly in cross-sectional studies with highly 
variable methodologies and results ranging from 503€-8862€ (Flachenecker et al., 2017; 
O'Connell et al., 2014). Most commonly, relapse costs were calculated as the difference 
between costs of patients with and without relapses without presenting characteristics of 
these distinct populations (Flachenecker et al., 2017; Hawton and Green, 2016). Less 
frequently, relapse associated costs were directly enquired in interviews (O'Connell et 
al., 2014). This methodology can be critically questioned because patients are required 
to differentiate between routinely utilized resources and relapse related resources. I ex-
tended the first mentioned approach by applying a PS matching. Each relapse active 
patient was assigned to a statistical twin, which was relapse inactive. I reported relapse 
costs stratified by patient and disease characteristics with estimated relapse costs rang-
ing between 690€ (age: 50+ years) and 1729€ (disease duration: <5 years). The 
matched and unmatched total relapse cost estimates differed by up to 23% due to the 
heterogeneity in patient and disease characteristics in the respective populations. The 
wide range of relapse costs suggests that precision of cost estimates in future economic 
evaluations in MS will increase if patient and disease characteristics are considered.  
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Former studies hypothesized that relapses may have a stronger effect in patients with 
limited permanent disability, however, a systematic investigation of this hypothesizes re-
mained unfulfilled (Kobelt et al., 2006a). With regard to the analysis, I can confirm that 
patients with a less severe burden of disease (mildly disabled, short disease duration) 
are more likely to incur high relapse costs predominantly due to higher indirect costs. 
These patients are more frequently employed resulting in higher costs due to sick leave. 
The results complement the findings of O’Brien who showed that relapse costs varied 
with relapse severity (O'Brien et al., 2003). 
A recent systematic review found that the most notable increase in relapse costs was 
associated with inpatient treatments, physician consultations, informal care and sick 
leave (Naci et al., 2010). The present analyses confirmed these findings. 
Inpatient treatment during a relapse might be indicative of a severe relapse (O'Brien et 
al., 2003; O'Connell et al., 2014). In the investigated population inpatient care costs were 
lower than previously assumed (Flachenecker et al., 2017). This could partly be ex-
plained by the inclusion criteria, which require patients to be treated with DMTs. DMTs 
can affect the disease course by slowing disease worsening, reducing the frequency and 
the severity of relapses (Giovannoni et al., 2016; Haas et al., 2019; Sanchirico et al., 
2019; Vercellino et al., 2009). As confirmed by the present results, fingolimod has shown 
to reduce healthcare resource utilization during relapses (Haas et al., 2019; Raimundo 
et al., 2013).  
Despite the increase in resource costs during relapses, I found that resource cost utili-
zation decreases in the post relapse phase. However, costs partially remained above 
the initial cost level. Interestingly, this was particularly observed in patients with RAW for 
resources that are notably increased during periods of relapses (inpatient stays, physi-
cian consultations, informal care, and sick leave). This might indicate an incomplete re-
covery with residual disability (Kalincik, 2015). This result is in line with recent findings, 
showing the high frequency of post-relapse residual disability (Achiron et al., 2018). 
 
5.4 Discussion of the Multiple Sclerosis Health Resource Survey 
A prerequisite for the CoI analyses was an instrument for resource use measurement 
with good psychometric properties. Even though CoI studies have a long tradition in MS, 
there were no validated instruments public available (DIRUM, 2019). Therefore, I devel-
oped and psychometrically assessed the MS-HRS. The results confirm that the MS-HRS 
represents a reliable, valid and easy to administer questionnaire providing a holistic as-
sessment of resource utilization for patients with MS. Health-resources were derived 
from all pathways of pwMS into an adapted health-resource model for MS. 
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Some very respectable efforts have already been taken to research the health economic 
footprint of MS (Ernstsson et al., 2016; Karampampa et al., 2012a; Kobelt et al., 2006a; 
Kobelt et al., 2017b). In Europe, Kobelt et al. repeatedly assessed costs and burden of 
MS in a cross-sectional survey approach including direct, indirect and intangible costs 
(Kobelt et al., 2006a; Kobelt et al., 2017b). Concepts and definitions of sub costs may 
differ over time with respect to scope and style of reporting, for example on intangible 
costs where a clear line is recommended (Wundes et al., 2010). For the model approach, 
I gave strong emphasis on the direct and indirect costs as Karampampa et al. and Reese 
et al. did with their models (Karampampa et al., 2012a; Reese et al., 2011). 
I increased the depth of the assessment of indirect costs by adding a quantification of 
costs due to presenteeism in addition to costs of absenteeism (sick leave, disability pen-
sion).  
Part of the questionnaire development was a validation process that confirmed reliability 
and validity in a way that no previous approach did within the MS domain (Figure 14). 
Kobelt et al. also recognized the need for validation, but a systematic approach beyond 
the aspects of practicability and face validity remained a task to fulfill (Kobelt et al., 
2019b). Even though I did not develop a one-dimensional questionnaire for a latent con-
struct, I was able to demonstrate essential psychometric qualities in the health economic 
assessment of MS. As of today, a multi-domain open-access database of resource-use 
questionnaires did not contain a published instrument for MS (DIRUM, 2019). Most of 
the cost assessments for MS were not developed to be published for general use but for 
the application in certain cross-sectional frameworks. A very recent analysis of real-life 
cost outcomes underlined the rising interest in longitudinal assessment of health-re-





Figure 14: Development process of the MS-HRS. 
Reproduced without modifications from Ness et al. (2020a). 
 
Compared to the results of Flachenecker et al. (2017), the proportion of patients claiming 
certain health services was slightly lower than in the present population. Particularly no-
ticeable was the lower proportion of patients taking over-the-counter (OTC) medication 
and investments. This may be explained by the less severe disease progression beyond 
a RRMS profile. Taking this into account, the average annualized burden of disease lied 
within the range expected from previous publications (Karampampa et al., 2012a; Kobelt 
et al., 2006a; Reese et al., 2011). 
Whereas Kobelt et al. have recently reported precise price tags for most unit costs, other 
authors have at least provided an indirect description of the valuation process and its 
exact results (Karampampa et al., 2012a; Kobelt et al., 2017a). Differences were found 
for the valuation of sub-costs, like inpatient hospitalization, due to different sources of 
valuation or different definitions for health-resource units. In any case, a precise and fully 
transparent reporting of per-unit costs is highly recommended, especially for main cost 
drivers. 
Event-related costing can also be considered of interest but a clear separation from costs 
being assessed via routine data collection is necessary (Karampampa et al., 2012a). 
Otherwise, costs may double due to double assessment. I discussed in an expert group 
whether to collect information both on sick days and on missed working hours as de-
scribed by Reilly et al (Reilly et al., 1993). Furthermore, asking for sick hours would have 
66 
 
meant switching to a recall period of seven days while the remaining questionnaire co-
vers the last six months. Due to higher usability, I decided to assess sick days only.  
Claims data were considered for the assessment of criterion validity. However, they have 
the disadvantage that only billing-relevant data is available preventing taking a societal 
perspective. Information on informal care, OTC medication, presenteeism and partially 
on investments and medical consumables are not recorded. In addition, claims data do 
not provide the number of physician visits of a patient in Germany. In consequence, 
claims data were not suitable for the validation process. 
Health economic studies often require both clinical and economic data. The MS-HRS 
can easily be used as part of clinical interventional and non-interventional studies to col-
lect economic data. In a large population of two non-interventional multicenter studies 
the questionnaire was easy to administer and has good psychometric properties. These 
characteristics provide the prerequisites for high-quality health economic studies, e.g. 
cost-effectiveness analyses. 
 
5.5 Generalizability of the study results 
The study population represented typical patient characteristics for a clinical RRMS pop-
ulation: patients were about 41 years old with a mean disease duration of 7 years. About 
three quarter of patients were female. To ensure representativeness, I used data from 
two large observational, prospective studies in which patients were documented homog-
enously across Germany. Representativeness towards a real-world setting was sup-
ported by the fact that no explicit exclusion criteria, except contraindications associated 
with current DMTs, had been stated for the (sub)studies PEARL and PANGAEA. High 
data quality was further achieved through standardized case report forms and the use of 
external validation checks at the time of data entry. Therefore, it might be assumed that 
the study results can be generalized to the wider MS population in Germany. Caution is 
required when transferring results to other countries in which healthcare systems have 
different reimbursement and treatment regimes. 
 
5.6 Limitations of the study 
For all analyses, I excluded patients with baseline EDSS ≥6 to ensure a balanced mild 
to moderate disabled study population. Corresponding data on severely disabled pa-
tients are not yet available but consecutive studies addressing this population are already 
being conducted (Haase et al., 2018a). The study results are based on patient-reported 
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data on resource utilization, which may not be completely free of biases. To avoid po-
tential conflicts, data were collected with the validated MS-HRS in a longitudinal format.  
 
Focusing on the disability worsening analyses, definitions of PIRA and RAW are solely 
based on EDSS, which means that the limitation of the EDSS also applies to the analysis. 
Particularly noteworthy is the focus on functional mobility and insensitivity on MS-related 
impairments like cognition. To address this problem, novel composite measures addi-
tionally include Nine-Hole Peg Test and Timed 25-Foot Walk to detect composite PIRA 
and RAW events (Kappos et al., 2018b). Nevertheless, as the definitions are solely 
based on EDSS, the analyses are less demanding and easier to implement in non-inter-
ventional studies.  
A small proportion of patients utilized direct non-medical resources with a high variability 
of costs, which might result from the low disability level in the study population. In con-
sequence, confidence intervals were conspicuously wide. Former analyses have shown 
that utilization of direct non-medical resources radically increase in more severely disa-
bled patients (Flachenecker et al., 2017). To better understand the effect of PIRA and 
RAW on direct non-medical costs, further analyses in more disabled populations may be 
helpful.  
 
In the relapse cost analyses, I compensated for variation between patients with and with-
out relapses by applying a PS matching. PS matching is a powerful technique to reduce 
imbalances in observable outcomes between populations. However, it cannot address 
unknown or unmeasured differences. Furthermore, I did not include corticosteroid med-
ication costs, which could have led to an underestimation of relapse costs.  
The MS-HRS is a patient-centered questionnaire and therefore subject to notable limita-
tions. Reliable recall periods of health-resource use are time-limited, especially in pa-
tients that are cognitively more affected by the disease. Furthermore, patients may not 
want to disclose socioeconomic and health economic information because it is consid-
ered too confidential. Further resource items were discussed to include into the analysis 
like crowd-funded therapies or cost-related voluntary work loss. However, these costs 
are unlikely to affect the economic burden on a societal level. In future studies, price tags 
for cost components have to be updated and adapted to local levels. For patients with 






For the case of MS, disability worsening and relapses might be focused in medical re-
search to reduce the societal economic burden. Disability worsening is associated with 
a tremendous societal economic burden in patients with MS. Both PIRA and RAW lead 
to significant increases in direct medical and indirect work-related costs compared to 
patients achieving DAF status. Accordingly, it is highly important from a societal perspec-
tive to delay or even prevent the transition into the progressive phase of MS. That is 
another argument for treating MS patients early with appropriate DMTs.  
Furthermore, relapses significantly increase the societal economic burden of MS. Partic-
ularly young patients and those with a recent diagnosis incur high relapse costs. The 
prevention of relapses in these patients should be a particular focus to reduce the eco-
nomic burden. In addition, it should be ensured that patients are diagnosed quickly to 
get the best available treatment.  
Further studies on the incidence and prevalence of disability worsening and relapses are 
demanded to assess financial risks for health systems and optimizing health service 
planning in patients with MS. 
As part of the study, I psychometrically assessed and published the MS-HRS. The MS-
HRS provides a holistic cross-sectional and longitudinal assessment of resource utiliza-
tion in patients with MS in the German health care setting. Further country-specific cost-






7 Summary  
7.1 English version 
Background 
Multiple sclerosis (MS) is a chronic, incurable disease of the central nervous system 
(CNS) and a potentially severe cause of neurological disability throughout adult life. Typ-
ically diagnosed between the ages of 20 and 40, the disease is associated with a se-
verely impaired health-related quality of life and a high societal economic impact.  
About 85% of patients are initially diagnosed with relapsing-remitting MS (RRMS), which 
is characterized by the unpredictable occurrence of relapses. Clinically, a relapse is de-
fined as a worsening or appearance of new neurological symptoms followed by a period 
of partial or complete recovery (relapse without worsening, RWW). Up to 80% of patients 
transit to the secondary progressive course (SPMS) within 20 years. SPMS is marked 
by an accumulation of irreversible disability either resulting from relapse-associated 
worsening (RAW) or progression independent of relapse activity (PIRA).  
Even though health economic assessments are well established in MS, implications of 
relapses and disability worsening on societal economic costs have scarcely been stud-
ied. Regarding disability worsening it is known that annual costs increase with increasing 
disability from 21,174–28,200€ (EDSS 0–3) to 39,923–44,000€ (EDSS 4–6.5) (in 2015 
values). However, the impact of PIRA and RAW on societal costs remains not well un-
derstood.  
Research to date has shown that the societal economic burden of MS increases in peri-
ods of relapses with most recent estimates at 2468€ per relapse (in 2015 values). The 
results of relapse cost analyses are inconsistent between studies since relapses and 
associated costs can vary across and within individuals depending on disease severity, 
disease duration, age, gender or therapy. However, a comprehensive test of this hypoth-
esis is still needed. 
 
Research aims 
I investigated the societal economic costs of disability worsening and relapses in patients 
with MS. First, I determined the societal economic costs of patients achieving disease 
activity free status (DAF, neither relapses nor disability worsening) and compared them 
with those having PIRA and RAW events. Second, I estimated direct and indirect relapse 
costs and determined differences in costs related to patient characteristics. Furthermore, 






Two-year clinical and pharmacoeconomic data were derived from two single arm, pro-
spective, multicenter, non-interventional long term studies conducted in Germany apply-
ing the Multiple Sclerosis Health Resource Survey (MS-HRS). The MS-HRS estimates 
the MS-associated direct and indirect costs from a societal perspective using the most 
accurate form of bottom-up microcosting. Costs are presented per quarter in 2011 Euros.  
PIRA and RAW events were indicated through a roving confirmed disability worsening 
(CDW) measure and corresponding relapse assessments. CDW is based on a prede-
fined increase on the Expanded Disability Status Scale (EDSS) sustained over at least 
6 months.  
The effects of PIRA and RAW on total, direct medical, direct non-medical and indirect 
societal economic costs are adjusted for age, gender and EDSS. Due to the right skew-
ness of cost data, I applied a Generalized Linear Mixed Model (GLMM) with a negative 
binomial distribution. Patients achieving DAF were assigned as the reference group. 
I calculated relapse costs as the difference in quarterly costs between propensity score 
(PS) matched patients with and without relapses (1:1 ratio). Statistical differences in re-
lapse costs between patient and disease strata were derived from a Generalized Linear 
Model (GLM) with a negative binomial distribution. For relapse active patients, I addition-
ally calculated the difference between quarterly costs prior- and during relapse and de-
termined costs in the post-relapse quarter.  
 
Results 
Overall, 1959 patients were analyzed with typical patient characteristics for a clinical 
RRMS population. Patients reported an average age of 41.62±10.04 years and were 
mostly female (73%). The mean disease duration was 7.30±5.95 with a mean baseline 
EDSS value of 2.26±1.37. 
Total mean quarterly societal economic costs including disease-modifying therapies 
(DMTs) were 6929€±2886€ per patient averaged over two years. Excluding DMTs, pa-
tients achieving DAF status had total mean quarterly costs of 1703€±2489€. PIRA 
caused 29% (IRR: 1.29; 95% CI 1.06–1.50, p<0.05) higher total costs compared to DAF. 
On the contrary, RAW increased total costs by factor 1.56 (95% CI 1.30–1.87, p<0.001). 
The effect of PIRA and RAW was striking for direct medical costs which increased by 
factor 1.48 (95% CI 1.13–1.95, p<0.01) and 2.25 (95% CI 1.72–2.94, p<0.001), respec-
tively. 
In the relapse cost analyses, a total of 1882 patients were included encompassing 607 
(32%) relapse-active patients. After PS-matching, 597 active and inactive patients were 
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retained. Relapse costs ranged between 690€ (age: 50+ years) and 1729€ (disease du-
ration: <5 years). In mildly disabled and recently diagnosed patients, indirect relapse 
costs (range: 971€-1093€) constantly outweighed direct costs (range: 535€-636€). The 
increase from prior- to relapse quarter was strongest for inpatient stays (+364%, 390€; 
p<0.001), day admissions (+241%, 53€; p<0.001) and absenteeism (+127%, 419€; 
p<0.001). In the post-relapse quarter direct costs and costs of absenteeism remained 
elevated for patients with relapse associated worsening. 
 
Conclusion 
For the case of MS, disease activity should be a focus in medical research to reduce the 
societal economic burden of the disease. Disability worsening is associated with signifi-
cantly higher societal economic costs compared to DAF status in patients with MS. Ac-
cordingly, it is highly important from a societal perspective to delay or even prevent tran-
sition into the progressive phase of MS. That is another argument for treating MS patients 
early with appropriate DMTs. Furthermore, relapses significantly increase the societal 
economic burden of MS. From a health economic societal perspective, the prevention of 




7.2 German version 
Hintergrund 
Multiple Sklerose (MS) ist eine chronische, unheilbare Krankheit des zentralen Nerven-
systems (ZNS) und eine potenziell schwerwiegende Ursache für neurologische Behin-
derungen im Erwachsenenalter. Typischerweise wird die Krankheit im Alter zwischen 20 
und 40 Jahren diagnostiziert und ist mit einer stark beeinträchtigten gesundheitlichen 
Lebensqualität und hohen ökonomischen Auswirkungen für die Gesellschaft verbunden.  
Bei etwa 85% der Patienten wird zunächst eine schubförmig-remittierende MS (RRMS) 
diagnostiziert, die durch das unvorhersehbare Auftreten von Schüben gekennzeichnet 
ist. Klinisch ist ein Schub als Verschlechterung oder Auftreten neuer neurologischer 
Symptome definiert, die von einer Periode der teilweisen oder vollständigen Rückbildung 
(RWW) gefolgt ist. Bis zu 80% der Patienten gehen innerhalb von 20 Jahren in den se-
kundär progredienten Verlauf (SPMS) über. Dieser ist durch eine Akkumulation von irre-
versiblen Behinderungen gekennzeichnet, die entweder aus einer schubassoziierten 
Verschlechterung (RAW) oder einer schubunabhängigen Progression (PIRA) resultie-
ren. 
Obwohl gesundheitsökonomische Analysen bei MS etabliert sind, wurden die Auswir-
kungen von Schüben und Behinderungsprogression auf die sozioökonomischen Kosten 
bisher wenig untersucht. Hinsichtlich des Behinderungsstatus ist bekannt, dass die jähr-
lichen Kosten mit zunehmender Einschränkung von 21.174-28.200€ (EDSS 0-3) auf 
39.923-44.000€ (EDSS 4-6,5) steigen (in Beträgen des Jahres 2015). Der Einfluss von 
PIRA und RAW auf die sozioökonomischen Kosten ist jedoch unklar.  
Darüber hinaus hat die bisherige Forschung gezeigt, dass die sozioökonomische Belas-
tung durch MS während der Schubperiode steigt. Die aktuellsten Schätzungen liegen 
bei 2468 € pro Schub (in Beträgen des Jahres 2015). Jedoch schwanken die Ergebnisse, 
da Schübe und die damit verbundenen Kosten je nach Schwere der Krankheit, der 
Krankheitsdauer, dem Alter, dem Geschlecht oder der Therapie bei ein und demselben 
Patienten und zwischen Patienten variieren können. Diese Hypothese bedarf jedoch 
noch einer genaueren Untersuchung. 
 
Forschungsziel 
Ziel der vorliegenden Arbeit ist es, die sozioökonomischen Kosten der Behinderungspro-
gression und der Schübe bei Patienten mit MS zu untersuchen. Zuerst werden die sozi-
oökonomischen Kosten für Patienten geschätzt, die frei von Krankheitsaktivität (DAF) 
sind. Diese werden anschließend mit den Kosten von Patienten verglichen, welche 
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Krankheitsaktivität in Form von PIRA und RAW vorweisen. In einem zweiten Schritt wer-
den die direkten und indirekten Schubkosten analysiert und Unterschiede in Bezug auf 
Patienten- und Krankheitseigenschaften aufgezeigt. Im letzten Schritt wird der ökonomi-
sche Einfluss von Schüben in der Post-Phase des Schubes analysiert.  
 
Methodik 
Datengrundlage bilden klinische und pharmakoökonomische Daten aus zwei einarmi-
gen, prospektiven, multizentrischen, nicht-interventionellen, deutschen Langzeitstudien, 
in denen der Multiple Sclerosis Health Resource Survey (MS-HRS) verwendet wurde. 
Der MS-HRS ermittelt die MS-assoziierten direkten und indirekten Kosten aus gesell-
schaftlicher Perspektive mit hoher Genauigkeit (Bottom-up Microcosting). Die Kosten 
werden per Quartal in Preisen des Jahres 2011 berichtet.  
PIRA und RAW wurden auf Grundlage bestätigter Behinderungsprogression (CDW) und 
zugehörigen Schubevaluationen identifiziert. CDW basiert auf einem vordefinierten An-
stieg auf der Expanded Disability Status Scale (EDSS), der nach 6 Monaten bestätigt 
wird.  
Der Effekt von PIRA und RAW auf die totalen, direkten medizinischen, direkten nicht-
medizinischen sowie indirekten sozioökonomischen Kosten wurde für das Alter, Ge-
schlecht und EDSS-Wert der Patienten adjustiert. Aufgrund der rechtsschiefen Vertei-
lung der Kosten wurden die Effekte mit einem generalisierten gemischten linearen Model 
(GLMM) geschätzt. Patienten, die frei von Krankheitsaktivität sind, wurden als Referenz-
gruppe verwendet.  
Schubkosten wurden als Differenz der vierteljährlichen Kosten zwischen gematchten Pa-
tienten (Propensity Score Matching) mit und ohne Schub berechnet. Die statistischen 
Unterschiede der Schubkosten zwischen Patienten- und Krankheitseigenschaften wur-
den mit einem generalisierten linearen Model (GLM) mit einer negativen Binomialvertei-
lung berechnet. Zusätzliche wurden für die schubaktiven Patienten die Differenz der Kos-
ten zwischen dem Prä-Schubquartal und Schubquartal sowie die Kosten in dem Post-
Schubquartal ermittelt.  
 
Ergebnisse 
Insgesamt wurden 1959 Patienten mit RRMS-typischen Patientencharakteristika analy-
siert: Die Patienten waren im Durschnitt 41,62±10,04 Jahre alt und überwiegend weiblich 
(73%). Im Mittel betrug die Krankheitsdauer 7,30±5,95 Jahre und der durchschnittliche 
EDSS-Wert lag bei 2,26±1,37 Punkten.  
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Die mittleren vierteljährlichen sozioökonomischen Kosten einschließlich krankheitsmodi-
fizierender Therapien (DMTs) betrugen 6929€±2886€ pro Patient im Zweijahresdurch-
schnitt. Patienten, die keine Krankheitsaktivität zeigten, verursachten durchschnittliche 
Gesamtkosten von 1703€±2489€ (exkl. DMTs) pro Quartal. PIRA bewirkte eine signifi-
kante Steigerung der totalen Kosten um durchschnittlich 29% (IRR: 1,29; 95% CI 1,06-
1,50, p<0,05). Hingegen führte RAW zu einer Steigerung der totalen Kosten um den 
Faktor 1,56 (95% CI 1,30-1,87, p<0,001). Besonders tragend war der Effekt von PIRA 
und RAW bei den direkten medizinischen Kosten, die um den Faktor 1,48 (95% CI 1,13-
1,95, p<0,01) bzw. 2,25 (95% CI 1,72-2,94, p<0,001) stiegen.  
In die Schubkostenanalyse wurden insgesamt 1882 Patienten einbezogen, von denen 
607 (32%) schubaktiv waren. Nach dem PS-Matching wurden 597 aktive und inaktive 
Patienten für die weitere Analyse beibehalten. Die totalen Schubkosten lagen zwischen 
690€ (Alter: 50+ Jahre) und 1729€ (Krankheitsdauer: <5 Jahre). Bei minimal bis mä-
ßiggradiger Behinderung und Patienten mit kurzer Erkrankungsdauer überstiegen die 
indirekten Schubkosten (Spannweite: 971€-1093€) stets die direkten Schubkosten 
(Spannweite: 535€-636€). Der Kostenanstieg vom Prä-Schubquartal zum Schubquartal 
war am stärksten bei stationären Aufenthalten (+364%, 390€; p<0,001), ambulanten Auf-
enthalten (+241%, 53€; p<0,001) sowie Krankheitstagen (+127%, 419€; p<0,001). Bei 
Patienten mit RAW blieben die direkten Kosten sowie Kosten für Krankheitstage erhöht.  
 
Fazit 
Um die wirtschaftliche Belastung der MS zu verringern, sollte in der medizinischen For-
schung die Krankheitsaktivität fokussiert werden. Behinderungsprogression führt zu sig-
nifikant erhöhten sozioökonomischen Kosten im Vergleich zu Patienten, die frei von 
Krankheitsaktivität sind. Dementsprechend ist es aus sozioökonomischer Perspektive 
besonders wichtig, den Übergang in die progressive Phase der MS zu verzögern oder 
sogar zu verhindern. Dies ist ein weiteres Argument für eine frühzeitige Behandlung mit 
geeigneten DMTs. Weiterhin erhöhen Schübe die sozioökomonomische Belastung er-
heblich. Eine besondere Relevanz gilt Schüben bei jungen Patienten und solchen Pati-
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Multiple Sclerosis Health Resource Utilization Survey (MS-HRS) 
 
The purpose of this questionnaire is to determine the total cost of a multiple sclerosis 
therapy. Due to the lack of complete data, it is often difficult to estimate the costs. Your 
contribution to our efforts to better understand these costs is therefore of particular im-
portance. 
 
When answering the questions, please note that the period for cost collection refers to 
the last 6 months. Please answer the questions one by one, any shortcuts between the 
questions will be announced. 
 
Thank you very much. 
 
I. Core questions (1 to 12) 
 
1. What is your current job? 
( ) Employed 
( ) Self-employed 
( ) Looking for work 
( ) Housewife/man 
( ) In study/training 
( ) Retired due to MS to a degree of ___% 
( ) Retired for other reasons 
 ( ) Other 
 
 




3. How many days have you been on sick leave due to MS in the last 6 months? 





4. Due to my MS, my state of health has reduced my productivity at work (e.g. concen-
tration or speed at work) in the last half year. (Choose a high number if MS affected 
your work a lot) 
 
 ( ) 0 ( ) 1 ( ) 2 ( ) 3 ( ) 4 ( ) 5 ( ) 6  ( ) 7 ( ) 8 ( ) 9  ( ) 10 
No effect 





5. Due to my MS, I have been hospitalized in a hospital, rehabilitation clinic or nursing 
home (including overnight stay) in the last 6 months. 
 
( ) No  → Proceed to question 6.  
( ) Yes, in detail: 
Of which ____ were days in a hospital, and thereof ____ days in neurology. 
Of which ____ were days in a rehabilitation clinic. 
Of which ____ were days in a nursing home. 
 
6. Due to my MS, I have been treated in a hospital, a rehabilitation clinic or a nursing 
home, i.e. in a day clinic (without an overnight stay) or a night clinic (without a day 
stay) in the last 6 months. 
 
( ) No  → Proceed to question 7. 
( ) Yes, in detail: 
Of which ____ were days in a hospital, and thereof ____ days in neurology. 
Of which ____ were days in a rehabilitation clinic. 





7. Due to my MS, I have had contact with the following specialists or professional 
groups on an outpatient basis in a practice or hospital in the last 6 months. Please 
only list those contacts that have not already been reported in question 5 or 6. (Mul-
tiple entries of different specialists are possible) 
 
( ) I did not consult any of the professionals listed below.  → Proceed to question 8. 
( ) Yes, in detail: 
General practitioner / family doctor     ____ times 
Neurologist        ____  times 
Other specialist (e.g. urologist, ophthalmologist, psychologist) ____  times 
MS nurse        ____  times 
Physiotherapist       ____  times 
Occupational therapist      ____  times 
Optician        ____  times 
Speech therapist       ____  times 
Acupuncture        ____  times 
Other alternative healthcare      ____  times 
Other         ____  times 
 
8. Due to my MS, I have been in one of the following examinations for the last 6 months: 
Magnetic Resonance Imaging (MRI), Computer Tomography (CT), Lumbar Puncture 
or Blood Examinations. 
 
( ) No  → Proceed to question 9.  
( ) Yes, in detail: 
______ Magnetic Resonance Imaging (MRI) (count) 
______ Computer Tomography (CT) (count) 
______ Lumbar Puncture (count) 
______ Blood Examinations (count) 





9. Due to my MS, I have needed help in the household or with everyday tasks within 
the last 6 months. 
 
( ) No  → Proceed to question 10.  
( ) Yes, by the following persons: 
 Professional care specialist (nursing service)  ____ hours per week on average 
Domestic help or personal advisor   ____ hours per week on average 
 Friends or family members    ____ hours per week on average 
 
10. How much (in Euro) have you spent on over-the-counter medicines to treat MS symp-
toms over the last 6 months? 
_________ Euro 
 
11. How much (in Euro) have you spent on medical consumables (e.g. bandages, 
patches) approximately due to your MS during the last 6 months? 
_________ Euro 
 
12. Have you made any changes to your house, apartment or car in the past 6 months, 
or have you needed special equipment or aids due to your MS?  
 
( ) No (zero costs) → Proceed to question 13.  
( ) Yes, in detail: 
Changes to your home due to problems related to your MS:  _________ Euro 
Changes to your car due to problems related to your MS:  _________ Euro 
For walking aids, wheelchair (manual or electric), electric scooter:  _________ Euro 
For a special hospital bed:       _________ Euro 





II. Additional questions (13 to 24) 
 
13. By how many hours per week did you have to permanently reduce your workload 
due to MS? (If not applicable, then „0“) 
____ hours 
 
14. Due to my MS, my earnings in the last 6 months have reduced by ... €. 
(If not applicable, then „0“) 
____ Euro 
 
15. Due to my MS, I had to change the type of work or my job in the last 6 months.  
( ) No 
( ) Yes 
 
16. Have your relatives reduced their working hours during the last 6 months to support 
you due to your MS? 
( ) No 
( ) Yes, from ___ hours per week to ___ hours per week 
 
17. Are you responsible for caring for other family members (e.g. relatives or children in 
need of care - including children in education)? 
( ) No 
( ) Yes 
 
18. What everyday tasks do you need help with? (Multiple answers possible). 
( ) Movement 
( ) Body care 
( ) Transport 
( ) Other 
 
19. What level of education have you acquired? 
( ) Secondary school 
( ) University degree 
( ) Completed vocational training 
( ) Without school leaving certificate 




20. Do you live ...? 
( ) Alone 
( ) Family/ partner 
( ) In a nursing home 
( ) Other 
 
21. Your health insurance status: 
( ) Statutory health insurance 
( ) Private health insurance 
 
22. I'm classified as ... . 
( ) Not handicapped  → Proceed to question 23. 
( ) Handicapped 
( ) Severely handicapped 
 
Degree of disability: 
______ % 
 
23. Your level of care: 
( ) None 
( ) ______ degree (number) 
( ) I don't know, but applicable 
 
24. Do you currently use one of the following devices due to your MS? 
(Multiple answers possible) 
( ) Sticks/Rollator 
( ) Wheelchair 
( ) Hospital bed 
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